



HAL
open science

Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease

Wei-Qin Zhao, Matthew Townsend

► **To cite this version:**

Wei-Qin Zhao, Matthew Townsend. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. *Biochimica et Biophysica Acta - Molecular Basis of Disease*, 2009, 1792 (5), pp.482. 10.1016/j.bbadis.2008.10.014 . hal-00562875

HAL Id: hal-00562875

<https://hal.science/hal-00562875>

Submitted on 4 Feb 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease

Wei-Qin Zhao, Matthew Townsend

PII: S0925-4439(08)00209-3
DOI: doi: [10.1016/j.bbadis.2008.10.014](https://doi.org/10.1016/j.bbadis.2008.10.014)
Reference: BBADIS 62882

To appear in: *BBA - Molecular Basis of Disease*

Received date: 3 August 2008
Revised date: 18 October 2008
Accepted date: 21 October 2008



Please cite this article as: Wei-Qin Zhao, Matthew Townsend, Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease, *BBA - Molecular Basis of Disease* (2008), doi: [10.1016/j.bbadis.2008.10.014](https://doi.org/10.1016/j.bbadis.2008.10.014)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

INSULIN RESISTANCE AND AMYLOIDOGENESIS AS COMMON
MOLECULAR FOUNDATION FOR TYPE 2 DIABETES AND ALZHEIMER'S
DISEASE

Wei-Qin Zhao¹ & Matthew Townsend²

¹. Alzheimer's Research, Merck Research Laboratories, West Point, PA 19486; ².
Neuroscience Drug Discovery, Merck Research Laboratories, Boston, MA 02115

To whom the correspondence is sent:

Wei-Qin Zhao, PhD
Alzheimer's Research
Merck Research Laboratories
770 Sumneytown Pike
44J116, PO Box 4
West Point, PA 19486
215 652 8519
wei-qin_zhao@merck.com

Abstract

Characterized as a peripheral metabolic disorder and a degenerative disease of the central nervous system respectively, it is now widely recognized that type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) share several common abnormalities including impaired glucose metabolism, increased oxidative stress, insulin resistance and amyloidogenesis. Several recent studies suggest that this is not an epiphenomenon, but rather these two diseases disrupt common molecular pathways and each disease compounds the progression of the other. For instance, in AD the accumulation of the amyloid-beta peptide ($A\beta$), which characterizes the disease and is thought to participate in the neurodegenerative process, may also induce neuronal insulin resistance. Conversely, disrupting normal glucose metabolism in transgenic animal models of AD that over-express the human amyloid precursor protein (hAPP) promotes amyloid-peptide aggregation and accelerates the disease progression. Studying these processes at a cellular level suggests that insulin resistance and $A\beta$ aggregation may not only be the consequence of excitotoxicity, aberrant Ca^{2+} signals, and proinflammatory cytokines such as $TNF-\alpha$, but may also promote these pathological effectors. At the molecular level, insulin resistance and $A\beta$ disrupt common signal transduction cascades including the insulin receptor family / PI3 kinase / Akt / GSK3 pathway. Thus both disease processes contribute to overlapping pathology, thereby compounding disease symptoms and progression.

Key words: Amyloid β oligomers; IAPP; Glucose metabolism; Excitotoxicity; Calcium; Serine & threonine phosphorylation, Synaptic plasticity; insulin receptor substrates; Akt; GSK3; Alzheimer's disease; Diabetes; neuronal insulin resistance; glucose metabolism; memory

AD: Alzheimer's disease
ADDL: Amyloid beta derived diffusible ligand
A β : Amyloid-beta peptide
A β 1–40: Amyloid beta peptide 1-40
A β 1–42: Amyloid beta peptide 1-42
ADDL: A β derived diffusible ligand
AMPA: α -Amino-3-hydroxy-5-methylisoxazole-4-propionic acid
AGE: Advanced glycation end-product
 α 7nAChRs: alpha-7-nicotinic acetylcholine receptors
ApoE4: Apolipoprotein E4
APP: Amyloid precursor protein
APV: (\pm)-2-amino-5-phosphonovaleric acid
BACE-1: β -site amyloid precursor protein cleaving enzyme-1
BAPTA-AM: 1,2-bis-(*o*-Aminophenoxy)-ethane-*N,N,N',N'*-tetraacetic acid tetraacetoxy-Methyl ester
CaMKII: Calcium/calmodulin-dependent kinase II
CNS: Central nervous system
CSF: Cerebrospinal fluid
EOAD: Early onset Alzheimer's disease
EphB2: Eph receptor B2
Eph receptors: erythropoietin-producing human hepatocellular carcinoma
FFA: Free fatty acid
fMRI: Functional magnetic resonance imaging
GABA: Gamma-Aminobutyric Acid
GLUT1: Glucose transporter 1
GSK3: Glycogen synthase kinase-3
hIAPP: Human islet amyloid polypeptide
IDE: Insulin degrading enzyme
IGF-1R: Insulin-like growth factor-1 receptor
IL-1: Interleukin-1
IL-6: Interleukin-6
IR: Insulin receptor
IRS-1: insulin substrate-1
JNK: c-Jun N-terminal kinase
LFS: Low frequency stimulation
LOAD: late onset Alzheimer's disease
LRP: lipoprotein receptor-related protein
LTD: Long-term depression
LTP: Long-term potentiation
MCI: Mild cognitive impairment
mIPSC: Miniature inhibitory postsynaptic currents
NFT: Neurofibrillary tangles
NIDDM: non-insulin dependent diabetes mellitus

NIRKO: Neuronal insulin receptor knockout
NMDA: N-methyl-D-aspartic acid
NEP: Neprilysin
NF- κ B: Nuclear factor kappa B
NR2B: NMDA receptor type 2B
PI3K: Phosphoinositide 3-kinase
PET: Positron emission tomography
PP1: Phosphatase 1
PSD: postsynaptic density
PTP1B: protein tyrosine phosphatase -1B
pTyr: Phosphorylated tyrosine receptor
RAGE: Receptor for advanced glycation end products
Ser/Thr: Serine/threonine
T2DM: Type 2 diabetes mellitus
Tg2576 mouse: Transgenic mouse expressing human mutant APP (HuAPP₆₉₅ SWE)
TNF- α : Tumor necrosis factor-alpha
TGN: Trans-Golgi Network

Introduction

In the United States, Type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) place huge burdens on our healthcare system and society. In 2004, complications related to diabetes was the sixth leading cause of death, while AD was seventh (<http://www.infoplease.com/ipa/A0005110.html>). A more recent estimate, has placed AD as the sixth-leading cause of death (http://www.actionalz.org/sixth_leading_cause.asp), with more dire projections as the average age of the population in first world countries continue to increase.

T2DM, a disorder of glucose regulation, is characterized by hyper-insulinemia, hyperglycemia and hypo-responsiveness of the insulin receptor (IR). Yet, T2DM has a clear cognitive component that includes impaired attention, memory and in the extreme, neurodegeneration [1]. Impaired memory performance becomes particularly evident in elderly T2DM patients [2]. With respect to epidemiology, each aspect of insulin resistance in T2DM (e.g. hyperinsulinaemia, hyperglycemia, glucose intolerance, adiposity, atherosclerosis, and hypertension) is an independent risk factor for AD [3]. Thus clinical studies reveal that patients who suffer from T2DM have a two- to three fold increased relative risk for AD, independent of the risk for vascular dementia [4-12].

AD is an age-related degenerative disease of the brain which is characterized by progressive dementia and loss of other cognitive abilities necessary for maintaining an independent living style. Notably, greater than 80% of AD patients have T2DM or show abnormal blood glucose levels [13]. Many excellent reviews have covered the historical framework for the hypothesis that neuronal insulin pathway is disrupted in both AD and T2DM [14-20]. The goal of this article is to place more recent experimental data in the context of this model, and underscore how each disease can contribute to the progression of the other. The first part of the article reviews the major common cellular/molecular pathologies in T2DM and AD. The second part summarizes experimental results illustrating interactions between the CNS insulin receptor signaling and neuronal/synaptic activities under physiological conditions, and the mechanistic bases for potential development of neuronal insulin resistance. Finally, the third part discusses the molecular interplay between neuronal insulin resistance and amyloid β ($A\beta$) aggregation, a central molecular pathology of AD. In this section, we will present experimental

evidence and theoretical foundation for a pathological loop formed between insulin resistance and amyloidogenesis that drives AD and T2DM progression.

ACCEPTED MANUSCRIPT

Table of content

Abstract

Introduction

1. Common pathological features between type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD):

1.1 Glucose and energy metabolism impairment in T2DM and AD

1.2 Insulin resistance as a common molecular feature in both T2DM and AD:

1.3 Amyloidogenesis is a common pathological feature in both AD and T2DM:

1.4 Elevated advanced glycation end product (AGE) is a shared feature in T2DM and AD

2. Current understanding of the brain insulin receptor functions

2.1. Central control of food intake and energy homeostasis

2.2. Insulin receptor in cognition

2.3 Insulin signaling in synaptic plasticity --- a modulator of the membrane excitability homeostasis?

2.4. Regulation of insulin receptor activity by synaptic/neuronal activities ---- implication of excitotoxicity and neuronal insulin resistance

3. Involvement of insulin signaling in AD pathogenesis: Interaction of brain insulin resistance and A β aggregation

3.1 A β abnormality in AD and the Synaptotoxicity of A β oligomers

3.2 Neuronal insulin receptor impairment as a direct target of A β oligomer toxicity

3.3 Mechanisms by which A β oligomers induce neuronal insulin resistance

3.3.1 A direct interaction between A β oligomers and IRs

3.3.2. Downregulation of IR expression on synaptic membrane surface

3.3.3. Negative regulation by serine/threonine phosphorylation derived from excessive excitatory activity and inflammation

3.3.4. A β oligomer induced insulin resistance at the blood brain barrier and other brain regions

3.4 Insulin resistance as a necessary cofactor for A β aggregation – the beginning of the vicious cycle?

5. Concluding remarks

1. Common pathological features between type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD):

1.1 Glucose and energy metabolism impairment in T2DM and AD: The biological basis of T2DM is a systemic and chronic impairment in glucose metabolism and utilization. Glucose metabolism is vital to the brain, since glucose oxidation is nearly the exclusive energy source required for neurons [21]. While representing only 2% of the body weight, the brain consumes 18-30% of total body glucose [22]. Therefore, disruptions of glucose supply, transport, and utilization result in neuronal damage and functional deficits. Indeed, in the developing human brain, hyperinsulinemia and hypoglycemia are accompanied by neuronal death and excitotoxic process such as seizure [23]. Severe chronic hypoglycemia can lead to permanent brain damage and mental retardation [23]. T2DM has long been shown to be associated with dementia [2,24-26]. The fact that significant cognitive disruptions are evident in elderly, but not middle- or younger-aged T2DM patients [2,25,27] suggests T2DM-originated pathologies (e.g. energy metabolism impairment and microvascular lesion) interact particularly with aging. Experimental diabetes in animal models shows a clear association of abnormal glucose metabolism and impaired memory and synaptic plasticity [25,28-36]. Thus disruptions in glucose metabolism can directly affect cognitive function.

Extensive clinical studies have demonstrated that glucose metabolism is also severely impaired in the cerebral cortex of the AD using the PET tracer fluoro-2-deoxy-D-glucose. The hypometabolism is most prominent in the posterior cingulate and parieto-temporal regions in early stages, but spreads to the prefrontal cortex as the disease progresses [37-46]. The reduced glucose metabolism can be detected in pre- or early stages of AD such as mild cognitive impairment (MCI) cases [47,48]. More interestingly, similar hypometabolism is detected in young and middle aged individuals carrying the apolipoprotein ApoE4 allele (who are at higher risk for developing AD [49] prior to the ability of neuropsychological tests to detect differences from normal individuals [38,39,50,51] and thus may not only be attributable to neuronal loss. While neither ApoE4 nor brain glucose metabolism has been validated to predict AD progression, results from these studies reveal an association between abnormal glucose metabolism and an AD genetic risk factor. Similarly, in transgenic animal models of AD, glucose metabolic reduction is found in the posterior cingulate regions of the mouse brain [52]. Disruptions of the amyloid precursor protein (APP), the protein central to the molecular

pathology of AD, either by deletion [53] or expression of a human mutant [54,55] have been shown to affect glucose metabolism and tolerance [56,57]. Finally, the glucose transporter 1 (GLUT1), a major glucose transporter selectively expressed in the endothelium of the blood brain barrier [58], is significantly reduced in aged humans and in transgenic mice and coincides with hippocampal atrophy [59], suggesting impaired glucose transport from the periphery into the CNS is correlated with neurodegeneration. These data demonstrate that impaired glucose distribution and utilization is a characteristic of AD.

1.2 Insulin resistance as a common molecular feature in both T2DM and AD: Insulin resistance is a critical feature of T2DM that may be detected 10-20 years before the clinical onset of hyperglycemia [60-62]. Insulin resistance is due to the reduced ability of the insulin receptor to respond to insulin stimulation [62]. Under this condition, the islet β -cells in the pancreas secrete higher levels of insulin to compensate for the declined receptor function making hyperinsulinaemia a common characteristic in T2DM patients. Although insulin receptors in the brain have distinct structure and functions from their peripheral counterpart [63], evidence indicates that excessive insulin levels are associated with functional decline in the central nervous system (CNS). For example, insulin levels usually rise with aging and are strong predictors of cognitive impairment in adults without diabetes [7,8,64]. Studies conducted with elderly subjects reported that elderly men with the highest insulin levels made 25% more errors on the Mini-Mental State Examination than men with the lowest insulin levels [7,8,65]. In their study with postmortem brain tissues, Frolich and colleagues first reported an increase in insulin binding activity in the brain regions of sporadic AD [66]. It is important to note, that despite the increased insulin binding, insulin receptor activity was reduced in the AD brain [67], consistent with insulin insensitivity. Recently a study conducted by Steen et al [68] showed that gene expression of a variety of molecules involved in insulin and insulin-growth factor signaling pathways were altered in the AD brain. Based on their findings, the investigators proposed that AD could be the type 3 diabetes [68]. Apart from the postmortem findings, Craft et al [69,70] compared, in a clinical study, the plasma and CSF insulin levels between 25 AD patients and 14 age-matched controls. Plasma hyperinsulinaemia was found in AD patients but not the age-matched controls, providing compelling evidence for an association of insulin resistance with AD. The association was further supported by transgenic AD mouse models. At age of 13 month, Tg2576 mice developed hyperinsulinaemia in the plasma, which could be prevented by treating

the mice with an insulin sensitizer, rosiglitazone [57]. A follow up study further showed that the rosiglitazone-corrected euinsulinemia was accompanied by improved cognitive performance in Tg2576 mice [71]. In addition, rosiglitazone also showed memory preserving effect in mild AD patients reported by Watson et al in a small scale clinical study [72]. Finally, factors that contribute to T2DM accelerate A β deposition in AD mouse models [73] while improved diet reduces A β deposition [74,75]. These data indicate that both hyperinsulinemia and impaired insulin receptor function which typify T2DM, are also commonly found in AD.

1.3 Amyloidogenesis is a common pathological feature in both AD and T2DM: Both AD and T2DM are amyloid forming diseases. Extracellular amyloid plaque in the brain is one of the principal pathological hallmarks of AD, in which the primary component is made by the amyloid beta peptide1-42 (A β) originated from the amyloid precursor protein (APP) via proteolytic cleavage [76,77]. Similarly, deposits of an amyloidogenic peptide are found in the pancreatic islets of Langerhans of T2DM patients. Although it was less well characterized compared to other diabetic pathological changes such as hyperglycemia and hyperinsulinaemia, the islet amyloid was found by ultra structural study, to contact β -cells of the T2DM islet [78]. The component of the islet amyloid deposit was subsequently identified as a 37-amino acid peptide and thus named islet amyloid polypeptide (IAPP) or amylin [79,80]. Under physiological conditions, IAPP is made in islet β -cells and co-secreted with insulin in a fixed ratio. It acts as both an adiposity and a satiety signal, combining functional aspects of insulin and glucagon in regulation of food intake and body weight [81,82]. Both human A β and IAPP exhibit sequence differences from their respective counterparts in mice [83]. While the human A β 1-42 and IAPP are highly prone to aggregation, the mouse A β peptides and IAPP do not form polymers [84]. As with AD mouse models that overexpress human APP and develop amyloid plaques, mice transfected with human IAPP together with diabetic traits develop IAPP oligomers and fibrils in the islet and show more severe diabetic symptoms [85]. This subject will be discussed in further details in section 3.4.

The evidence of A β oligomer toxicity on neurons together with multiple common features of IAPP with A β suggested that aggregates of IAPP could generate toxicity to islet β -cells in a way similar to A β oligomers do to neurons. Extensive studies in the past years have found that like A β 1-42, IAPP also forms early intermediate assemblies as spherical oligomers

[86,87] that are recognized by a soluble A β oligomer antibody [88] implicating that these oligomers possess a common folding pattern or conformation. The behavior of IAPP oligomers toward cultured β cells is similar to A β oligomers to neurons [89-93]. While the *in vivo* “true” IAPP oligomers remain to be isolated from the T2DM islets, these *in vitro* and *ex vivo* studies suggest a potential role of IAPP soluble oligomers in degeneration of the insulin producing β -cells in T2DM. Thus, although the nature of the toxic oligomer species and the mechanism by which they cause target cell damage have not been clearly understood, current evidence supports the notion that amyloid formation might be a basic cause for both AD and T2DM, as well as other protein deposition diseases [94-97].

1.4 Elevated advanced glycation end products (AGEs) and oxidative stress are commonly shared by T2DM and AD: Another common molecular pathology shared by both T2DM and AD is elevated levels of advanced glycation end products (AGEs) and the related oxidative stress. In late stage T2DM, chronic intermittent hyperglycemia leads to acceleration of AGEs generated by non-enzymatic glycation and oxidation of cellular proteins, lipids and nucleic acids by reducing sugars [98-103]. Both clinical and animal studies have shown that elevated blood glucose levels result in markedly increased accumulation of AGEs in tissues of diabetic subjects [98,104-107]. Besides hyperglycemia, aging and increased oxidative stress contribute significantly to AGE formation [101,108]. Accumulated AGEs bind to the cellular receptor (RAGE), a member of the immunoglobulin superfamily that is expressed on multiple cell types including endothelial cells, mononuclear phagocytes, vascular smooth muscle cells and microglia [109]. Interactions of AGEs with RAGE trigger signaling cascades involving upregulation of transcription factor NF- κ B [110]. This process leads to further increased oxidative stress and production/secretion of high levels of inflammatory cytokines such as IL-6 and TNF- α [98]. Thus the AGE-RAGE interaction represents an important source of inflammation and oxidative stress, and is associated with diabetic complications such as diabetic retinopathy, neuropathy, and cardiovascular lesions [98].

Accumulation of AGE is not unique to diabetes, but is closely associated with aging and neurodegenerative disease such as Alzheimer's disease [101-103,108,111-113]. Modification of A β by AGE markedly accelerates A β aggregation [114]. Glycation of tau stabilizes neurofibrillary tangles [115-117]. High levels of AGE immunoreactivity are present in AD plaques and neurofibrillary tangles [101,114,118-121]. This evidence indicates that accumulation of AGE in

the brain contributes to amyloidosis and neurofibrillary tangle formation. Moreover, present in brain endothelium, microglia and neurons, RAGE has been found to be a receptor for A β [122,123] and mediates A β induced microglia activation and subsequent inflammation in AD [124-129]. Interaction of A β with RAGE in neurons has been reported to mediate A β -induced disruption of LTP [130]. These data implicate elevated glucose levels in AGE-associated neurodegenerative processes.

2. Current understanding of the brain insulin receptor functions

Because neurons do not require insulin for glucose transport, the brain was considered a non-insulin targeting organ until approximately 30 years ago when widespread distribution of insulin receptor (IR) was detected in the brain [131,132]. A specific regional expression of IR mRNA with situ hybridization [133,134] and insulin binding with autoradiography [135] revealed that IRs are distributed in discrete areas including the olfactory bulb, pyriform cortex, hippocampus, amygdala, and hypothalamus. The highest concentrations of IR mRNA expression was found in the choroid plexus and cerebellum [100-102]. Interestingly, while the cerebellum has high levels of IR mRNA, only low levels of protein are detectable [101,102], presumably due to a high protein turnover rate of the receptor. At cellular/subcellular levels, IRs are enriched in neurons relative to the glia, and concentrated in synaptic membranes [135,136]. There is some evidence that insulin itself is expressed in the CNS [137-141] [349], albeit at low levels. Nevertheless, the role of CNS produced insulin is poorly understood.

Biochemical characterization of brain IRs indicates that by multiple criteria they are similar to the peripheral IR [142], yet they display a couple of key differences. First, due to alternative splicing, brain IRs have a lower molecular weight [143,144]. This is caused by deletion of the exon 11 encoding a sequence of 12 amino acids at the distal end of the α subunit [145-148]. IRs lacking exon 11 (A type) show a higher insulin binding affinity, differential glycosylation and a higher internalization rate than the exon 11-containing IR [149,150]. Moreover, a prominent functional difference between the brain and peripheral IRs is that brain IRs are dispensable as the primary and direct regulator of glucose transport and metabolism [151-153]. Instead, brain IRs exert diverse functions determined by the brain region where they are localized. The preponderance of evidence suggest that major functions of brain IR signaling

include the central regulation of body energy homeostasis, modulation of synaptic plasticity and cognition, and involvement in aging-related neurodegeneration.

2.1. Central control of food intake and energy homeostasis: One of the most extensively studied and so far best defined functions of the CNS IR is its central role in governing the body energy homeostasis exerted by insulin signaling from hypothalamus. Although the role of CNS insulin signaling in regulation of food intake, body weight control and reproduction has long been proposed [154-156], it has only been clearly confirmed recently that mice with selective deletion of neuronal insulin receptor (NIRKO) display food intake-dependent obesity and impaired reproduction [157]. While this aspect of brain IR function is beyond the scope of the present review, readers are referred to excellent review articles for detailed information [158-163].

2.2. Insulin receptor in cognition. Less understood are roles of CNS IRs in learning and memory. The abundant distribution of IRs in hippocampus, amygdala and cerebral cortex suggests that they play a role in synaptic activity and cognitive process. Indeed, animals experiencing spatial learning show an increased amount of insulin receptor [101] and insulin substrate-1 (IRS-1) [119] in synaptic membranes of the hippocampus. On the other hand, rats with deficits in β cell insulin production resulting from experimental diabetes show reduced insulin receptor in their hippocampus [32]. Insulin, when given to healthy human adults under euglycemic clamp to maintain normal blood glucose levels, results in activation of medial temporal lobe including the hippocampus revealed by functional MRI (fMRI) [164], a structure critically required for processing declarative memory [165]. Consistent with the induced brain activation, insulin was shown to exert cognition-enhancing effects in both human and experimental animals [166-169]. In recent years, a new delivery method of insulin has been tested, in which insulin is administered via an intranasal route to avoid insulin's peripheral effects. Individuals receiving insulin via this method show an elevated CSF insulin level, but unaffected plasma insulin levels [170] together with enhanced declarative memory such as recalling previous learned words [170,171]. Intranasal insulin administration improves attention and verbal memory of AD patients and individuals with MCI [172]. However, the treatment was shown to be only beneficial to non-ApoE4 carriers [173]. Involvement of insulin signaling in learning may be evolutionarily conserved in *C. elegans* [174]. Insulin-1 was found to be localized in AIA interneurons of *C. elegans* and required for chemotaxis learning [141].

2.3 Insulin signaling in synaptic plasticity --- a modulator of the membrane excitability homeostasis? Precisely how insulin signaling is involved in memory processing has been a topic of research for the past decade. Electrophysiology studies have revealed a role of synaptic signaling in long-term potentiation (LTP) and long-term depression (LTD), two primary well characterized forms of activity-dependent synaptic plasticity in the mammalian CNS [175-177]. Using a streptozotocin-induced experimental diabetic animal model, several studies have shown that both spatial learning and hippocampal long-term potentiation (LTP) are inhibited in diabetic animals [29,145]. The LTP deficit was prevented by insulin treatment [178]. Also observed in these animals was a marked decrease in the NR2B subunit of NMDA receptor [179]. While the severity of LTP deficits was related to hyperglycemia [29] implicating an indirect effect, direct inhibition of IR activity via the IR tyrosine kinase inhibitor AG1024 disrupts LTP in hippocampal brain slices [180]. However, a recent study by Stranahan et al suggests that diabetes-associated memory and LTP deficits may be mediated by a glucocorticoid-mediated mechanisms [36].

Multiple studies have demonstrated that insulin regulates inhibitory transmission and synaptic depression pathway by regulating AMPA and GABA receptor trafficking. The AMPA-type glutamate receptor mediates the vast majority of fast excitatory transmission at CNS synapses. They are the primary receptors responsible for basal synaptic transmission, activation of NMDA-type glutamate receptors, as well as expression of LTP and LTD [181-184]. Synaptic AMPA receptors are highly dynamic, showing rapid exocytosis and endocytosis [185]. Research over the past decade has reached a general consensus in the field that it is the regulated, rather than constitutive or ligand-induced endocytosis of AMPA receptor mediated via a clathrin-dependent mechanism, that reduces the number of the receptors on synaptic membrane surface and underlies synaptic LTD [186,187]. Using electrophysiology, molecular mutagenesis, pharmacology and confocal immunostaining, several labs have independently shown that application of insulin to neurons induces a rapid internalization of AMPA receptor via a clathrin-mediated pathway [188-191] thereby inducing LTD [152,155,157]. Moreover, insulin-mediated LTD shares the same mechanism as low frequency stimulation (LFS)-induced LTD, since these two types of LTD induction occlude each other [155]. These experiments demonstrate that insulin can regulate AMPA receptor trafficking that underlies synaptic transmission and synaptic plasticity. LTD mediated by AMPA receptor internalization has been shown to regulate

extinction of fear conditioned memory process [192], hence linking the insulin-involved synaptic activities to specific aspects of cognition. The paradox that insulin is found to promote both LTP and LTD was addressed in a study by van der Heide et al, in which the authors show that insulin shifts the stimulation frequency threshold for inducing LTD and LTP. Thus in the presence of insulin, 0.033Hz and 10Hz frequencies induce LTD and LTP respectively while in the absence of insulin, 1Hz and 100Hz frequencies are required [193]. These results suggest that insulin plays a modulatory role in activity-dependent synaptic plasticity via changes in membrane responsiveness to stimulation frequency. Consistent with this finding, Chiu et al [194] reported that transfection of a dominant-negative IR in optic neurons of *Xenopus* tadpole decreased synaptic density and AMPA currents following visual stimulation. These data indicate that insulin receptors in the CNS play a role in regulating synaptic structure and function.

In addition to AMPA and NMDA receptors, insulin has been shown to be a regulator of type-A GABA receptors. GABA(A) receptors are the principal inotropic GABA receptor in the CNS and mediate inhibitory synaptic transmission throughout the brain including hippocampus and cerebral cortex. Using HEK 293 cells expressing GABA(A) receptors, Wan and colleagues show that insulin causes a rapid recruitment of GABA(A) receptors from cytosol to the plasma membrane [195]. These receptors are functionally integrated into the membrane, since the authors observe enhancement of GABA(A) receptor mediated miniature inhibitory postsynaptic currents (mIPSC) following insulin treatment [162]. Following these findings, it is shown that insulin also affects muscarinic acetylcholine transmission-potentiated GABA currents [196]. Essential to the insulin-mediated effects on GABA neurotransmission and translocation is the PI3 kinase signal transduction pathway [197].

Similar to the effects of insulin on GABA receptors in the CNS, insulin potentiates glycine signaling, another inhibitory neurotransmitter, in spinal cord neurons [198,199]. In the presence of insulin, the amplitude, but not the frequency of glycine mIPSCs increases three fold compared with untreated cells. As with GABA(A) receptors the PI3K pathway is involved; however, insulin does not appear to cause translocation of glycine receptor in spinal cord primary neurons [165]. While methods vary between laboratories (such as insulin concentration, acute versus chronic application, cell type), the preponderance of evidence obtained so far points to a role for insulin and insulin receptors in the cycling of multiple neurotransmitter receptors into and out of synapses.

While *in vitro* studies suggest insulin receptors modulate multiple neurotransmitter systems, *in vivo* studies using the NIRKO mice (with selective deletion of neuronal insulin receptor) suggest only a modest role for the neuronal insulin receptors. Schubert et al. reported that these mice showed no deficits in learning tasks such as the Morris water maze or T-maze, nor alteration of brain glucose metabolism despite altered PI3K signaling and GSK3 activity [118]. Although a clear understanding has not been achieved, one explanation is that the hippocampus and the cerebral cortex express the IGF-1 receptor. Under physiological conditions, insulin and IGF-1 cross-react with IRs and IGF-1Rs. Moreover, the IR family shares many intracellular signaling pathways. The IR family is also thought to form heteromeric receptors containing both IR and IGF-1Rs [200]. Thus even though IGF-1 receptor levels were reported to be unchanged in the NIRKO mice, it is possible that the IGF-1 receptor could compensate for the lack of IRs. Indeed, in diabetic rats with severe insulin deficits, we have observed decreased IR expression accompanied by a slight but significant upregulation of IGF-1R in the hippocampus [32]. Given the amount of tau pathology in the NIRKO mice, it is surprising that these animals appear to be cognitively normal. However it is worth noting that the T2DM-associated cognition impairments mostly are not evident until age 65 or older [2,7,8,25,27,66], and that memory deficits in diabetic animals depend on disease duration [201]. Additional studies, therefore, with aged mice (the NIRKO mice were 7 weeks old) might reveal more evidence abnormal cognitive. Alternatively, an inducible siRNA knockdown of brain insulin and/or IR/IGF-1R could provide complementary data.

2.4. Regulation of insulin receptor activity by synaptic/neuronal activities ---- implication of excitotoxicity and neuronal insulin resistance: Much effort has been devoted to the effects of insulin signaling on synaptic and neuronal function. In contrast, little is known about how IRs in turn affected by synaptic activity. Studies on peripheral IRs reveal that IR tyrosine phosphorylation is regulated by multiple feedforward and feedback routes at both inter- and intra-molecular levels.

The IR is a membrane receptor tyrosine kinase, activated by tyrosine autophosphorylation of the β subunit upon insulin binding to the α subunit exposed to the extracellular surface [202,203]. The phosphorylated receptor subsequently activates several downstream signaling cascades primarily through insulin receptor substrates 1-6 (IRS1-6). Best studied in the periphery, activated IRs initiate signaling through phosphoinositide 3-kinase (PI3K), PDK-1 and

Akt/PKB [204]. Activation of this pathway leads to several responses: 1) GLUT4 translocation to the plasma membrane for glucose transport and uptake [205]; 2) glycogen synthesis-via Akt inhibition of GSK3, a kinase that is constitutively active and negatively regulates glycogen synthase [206]; and 3) lipogenesis via up-regulation of fatty acid synthase gene [207].

Under physiological conditions, the phosphorylation state of IRs is regulated by multiple tyrosine phosphatases including the protein tyrosine phosphatase-1B (PTP1B) [208,209]. Secondly, IR activity can be inhibited by serine/threonine (Ser/Thr) phosphorylation at the level of IR itself or on downstream signaling molecules such as IRS-1 [210-219]. For instance calcium has been shown to inhibit IR autophosphorylation subsequent to insulin binding [185], primarily via the activation of Ca^{2+} dependent Ser/Thr kinases such as PKC, Akt and MAP kinase [220-225]. Thirdly, IRs are regulated by receptor internalization, downregulation and desensitization. Upon insulin binding, IRs undergo rapid internalization to endosomes where they dissociate from insulin and are degraded [226-228] or recycled back to the plasma membrane [229,230].

Based on this evidence, it is likely that IRs in the brain can be negatively regulated by Ca^{2+} influx subsequent to excitatory or excitotoxic neurotransmission. Activation of excitatory glutamatergic receptors such as NMDA receptor induces Ca^{2+} influx at postsynaptic sites, which acts as a second messenger to stimulate an array of Ca^{2+} dependent Ser/Thr protein kinases such as PKC, Ca^{2+} /calmodulin-dependent kinase II (CaMKII), MAP kinases and Akt [231-241]. Indeed, in the presence of elevated calcium, insulin-stimulated IR tyrosine phosphorylation is markedly reduced in hippocampal synaptic preparations [101]. In hippocampal primary neuronal cultures, both glutamate and high K^+ induced depolarization have been shown to attenuate insulin-stimulated IR tyrosine phosphorylation. The effect is reversed by the NMDA receptor APV and memantine; neuronal activity blocker tetrodotoxin, and calcium chelator BAPTA-AM[242]. Thus, at hippocampal synapses, IRs not only modulate glutamatergic and GABAergic transmission, but are also regulated by calcium and calcium-dependent kinases arising from synaptic transmission [Figure 1].

The negative regulation of IR tyrosine phosphorylation by calcium and calcium-dependent kinase activities suggest a testable model for the molecular basis brain insulin resistance under pathological conditions. Excessive and aberrant excitatory transmission and calcium deregulation are thought to be involved in pathogenesis of neurodegenerative diseases such as AD [243-246]. Persistent excitotoxicity caused by high levels of glutamate

neurotransmission and abnormally elevated calcium signal could enhance Ser/Thr phosphorylation of the IR and IRS, thereby attenuate IR tyrosine kinase activity and downstream insulin signaling. In return, impairment of insulin signaling could compromise synaptic trafficking of AMPA receptors (endocytosis) and GABA(A) receptors (membrane translocation). Together with dysregulation of other insulin-modulated membrane proteins (Na⁺/K⁺ ATPase, for example) [247], this feedback loop could adversely affect the maintenance of synaptic membrane potential thereby further exacerbating the cell's control of membrane excitability.

3. Involvement of insulin signaling in AD pathogenesis: Interaction of brain insulin resistance and Ab aggregation

3.1 Ab abnormality in AD and the Synaptotoxicity of Ab oligomers: The most evident symptom of AD is a progressive memory loss. Although the etiology and epidemiology for the early onset (EOAD) and late onset AD (LOAD) may be quite different, the clinical symptoms and brain pathologies for both are indistinguishable with deposition of senile plaques in the parenchyma and vasculature accompanied by neurofibrillary tangles (NFT) in the intraneuronal compartment. Because of the common pathology, it is widely believed that A β plays a key role in the molecular mechanisms of early disease progression [248-250].

The A β ₁₋₄₀ and A β ₁₋₄₂ peptides are produced from sequential enzymatic cleavages of APP by the β -site amyloid precursor protein cleaving enzyme-1 (BACE-1) and the γ secretase complex (Tanzi and Bertam, 2005). Early onset AD is caused by mutations of APP [251,252] and presenilins 1 & 2 [253-256], which typically increase the levels of A β or propensity of A β to aggregate. The mechanism for accumulation of A β in LOAD, however, is not clear. It has been suggested that cleavage of the wild-type APP occurs at the endosome and/or along the endocytic pathway, since high efficiency of APP-BACE interactions are found in the endosome but not the trans-Golgi Network (TGN) and cell surface [257,258]. One hypothesis is that additional genetic factors including molecules that affect protein sorting within the endosome-TGN and/or endosome-membrane routes contribute to prolonging APP-BACE interactions which result in increased A β production [229]. In many cases, the genetic risk factors for AD are expected to elevate A β levels or the propensity for aggregation of A β in the brain.

It is generally believed that accumulation of A β leads to its aggregation, and it is these misfolded A β species that are detrimental to neuronal networks [259-262]. Compared to A β 1-40, A β 1-42 has high propensity to aggregate rapidly [263-265], forming multi-level intermediates from oligomers, protofibrils to plaque [250]. Among the multi-forms of A β 1-42, the soluble oligomers have been shown over the past 10 years to be the most toxic species to neurons [266,267]. In the brains of MCI patients that are not contaminated with senile plaques, the A β levels correlate with cognitive decline [268]. From the brain and CSF of AD patients, ADDLs, a term describing a combination of A β oligomeric species from trimer to 24mer or higher [269,270] are found to be markedly increased compared to age matched non-demented controls [271,272]. Similarly, in AD transgenic mice overexpressing mutated human APP, increases in A β production correlate closely with memory deficits in middle aged mice before plaque formation [54]. From both human AD brain and brains of transgenic mice, A β oligomeric species around 50-56kDa (equal to approximately 12 aggregated monomers) have been identified to exert neuronal toxic and memory impairing effects [273-275]. In addition, naturally secreted small A β oligomers (e.g. dimers and trimers) are also highly toxic to neurons [262,276]. It has been shown that small oligomers of A β , probably formed first as dimers intracellularly [277], are secreted into conditioned medium as stable dimers and trimers [276]. When the isolated oligomers or the conditioned medium containing these oligomers are applied to rat hippocampal slices or given to live animals, they blocked the LTP type of synaptic plasticity and inhibited memory formation [278,279]. These inhibitory effects are prevented by anti-A β antibody, gamma-secretase inhibitors and scyllo-inositol that inhibits the stability of A β oligomers [246, 247]. Furthermore, A β dimers were also detected and isolated from human CSF and brains of AD patients [280,281]. When given to animals and hippocampal slices, the dimer-specific CSF and brain tissue extract showed potent LTP and memory disrupting effects [248,249]. With synaptic immunochemical approaches, A β oligomers are shown to bind specifically to synaptic spines and cause disruptions to these structures [282,283]. The binding and synaptotoxic effects of these oligomers are blocked by anti-ADDL antibodies [284,285].

It is not yet clear why oligomeric forms of A β are particularly toxic to synapses at nanomolar concentrations compared to the monomers. For one thing, these oligomers are unusual structures that appear prominently only in disease. They arise from protein misfolding

due to certain cellular mechanistic defects that have not been clearly identified. During oligomerization, A β monomers are likely to undergo conformational changes [286] that may confer the ability to interact with surface receptors such as IRs and α 7nAChRs [287] which could disrupt normal cellular function. In this scenario, a conformational change in oligomerized A β acts as a “gain-of-function” pathogenic ligand [240, 313] on surface receptor/proteins leading to interruptions of normal neuronal function such as synaptic transmission and memory formation. Alternatively, oligomeric A β may be more toxic than its monomeric form because an enlarged peptide may sterically hinder the function of a membrane-bound protein such as a ligand gated receptor. In either case, synaptic transmission and downstream cellular events required for memory processing are likely to be interrupted (i.e. synaptic failure) and memory formation deficits would occur [95].

3.2 Neuronal insulin receptor impairment as a direct target of A β oligomer toxicity Although the molecular mechanisms by which A β and its oligomers induce synaptic degeneration and memory loss have yet been clearly understood, evidence is now emerging that neuronal insulin resistance in the AD brain is a direct consequence of A β oligomer toxicity. As described in the previous sections, impaired insulin receptor activity and plasma hyperinsulinemia are found in AD patients and transgenic animal models of AD [57,69,70]. Treating AD patients and transgenic animals with either insulin or insulin sensitizer reduces A β level and improves memory performance [71,139,140], suggesting a correlation between insulin resistance and AD. More recent evidence has demonstrated that neuronal insulin resistance is a direct consequence of A β oligomer toxicity. It is shown that the low-n A β oligomers inhibit the insulin-stimulated IR tyrosine phosphorylation and phosphorylation of several down stream kinases in hippocampal neurons [147]. When applied to hippocampal slices both A β oligomers and an IR tyrosine kinase inhibitor block LTP, an effect that is overcome by 1 μ M insulin [147]. Lee et al also reported similar results, which showed that A β oligomers were significantly more potent than A β 42 monomer in inhibiting LTP, and that insulin overcame A β -induced LTP deficits probably via inhibiting A β oligomerization [288]. This synaptic plasticity protection of insulin is consistent with insulin’s memory improving function in AD patients [139,140]. Independent results are also obtained with ADDLs. ADDLs at nanomolar concentrations inhibit the insulin-stimulated IR tyrosine phosphorylation in rat hippocampal primary neurons, and in human IR expressing

NIH3T3 cells [212]. Under the same condition, ADDLs do not affect IGF-1R tyrosine phosphorylation. Remarkably, ADDLs' binding to neurons causes a striking loss of IR α -subunit from the dendritic membranes; such that most ADDL bound neurons show the IR immunoreactivity to be translocated to the cell interior and nucleus, whereas neurons without ADDL binding showed intact IR immunoreactivities in dendrites [212]. A similar phenomenon appears to exist in the AD brain. In a recent study Moloney and colleagues [289] show a loss of IR immunoreactivity from neuronal processes and the periphery compartment of the cell body in brains of AD patients. In these AD neurons IR immunoreactivity is localized in the nucleus, whereas in neurons of non-AD brains the IR immunoreactivity is detected in both neuronal processes and the cell body. In correlation, a marked reduction in protein expression of IR and substrates IRS-1 and IRS-2 were found in the brains of both AD patients and transgenic animals [257]. Taking together, the evidence demonstrates IR impairment (insulin resistance) can result directly from A β oligomer toxicity, which may also be the situation in the AD brain.

3.3 Mechanisms by which Ab oligomers induce neuronal insulin resistance. Although it remains to be explored and clearly understood, several mechanisms may underlie the A β oligomer-induced IR impairment.

3.3.1 A direct interaction between Ab oligomers and IR: A β oligomers may disrupt IR function via a direct interaction. All A β species including monomers [290], low-n oligomers [147], and ADDLs [212] bind IRs. In one scenario A β has been proposed to compete with insulin for IR binding thereby hindering IR activation [258]. This is supported by the observation that insulin at a higher dose (1 μ M) overcomes the inhibition of LTP by A β oligomers [147]. Given the fact that both insulin and A β bind to and compete with the same degrading enzyme (IDE) [291], it is possible that they may also compete for binding to the IR. By contrast ADDL binding to IR is dependent on the tyrosine phosphorylation state of the IR [212]. Additional studies will be required to clarify whether and how A β affects insulin binding, insulin receptor conformation and/or insulin receptor expression (see below).

3.3.2. Downregulation of IR expression on synaptic membrane surface: A β oligomers may also disrupt synaptic IR function via removal of the receptor from synaptic surface [212]. In addition to IR, A β has been shown to cause loss of synaptic surface receptors including AMPA [292], NMDA, α 7-nicotinic receptors [255], and EphB2 tyrosine kinase receptors [240]. The

removal of most of these receptors is via A β -triggered endocytosis [255,260], and it accompanies severe loss of spine structures [240,247,249,260]. The IR is known to undergo rapid internalization upon insulin binding, a mechanism is thought to mediate insulin degradation and receptor downregulation [195]. It is not clear whether loss of the synaptic IR is induced by a ligand-like action of ADDLs, or simply an event accompanying synaptic spine removal. However, the fact that insulin overcomes A β oligomer-induced LTP inhibition [147] suggest a possible role for insulin signaling in these processes. In any case, persistently suppressing IR expression on neuronal surface may be an important mechanism by which accumulated A β oligomers cause insulin resistance in the brain.

3.3.3. Negative regulation by serine/threonine phosphorylation derived from excessive excitatory activity and inflammation: Brain insulin resistance could be enhanced by A β oligomer-associated excitotoxicity and inflammation. In the periphery, inflammatory factors such as TNF- α , free fatty acid (FFA) and their downstream effectors such as the c-Jun amino-terminal kinases (JNKs) have been identified as potent mediators for obesity-related insulin resistance and T2DM [293-295] via influences on serine phosphorylation of IR and IRS-1 [296,297]. Activities of PKC, Akt and several other kinases are involved in this pathway [298-301]. TNF- α has been shown to inactivate phosphatase 1 (PP1) [302,303] shifting the phosphorylation-dephosphorylation equilibrium to the left, resulting in enhanced Ser/Thr phosphorylation of IRS-1 and IR.

Although largely unappreciated, Ser/Thr phosphorylation-induced insulin resistance may be particularly relevant to the brain, as neurons are the most polarized and excitable cells in the body and rely critically on Ca²⁺ and Ca²⁺-dependent kinases for their functions. IR and IRSs are highly concentrated on the synaptic membranes, the primary sites where Ca²⁺ and other excitatory signals are generated, which would subject them to regulation by synaptic activities. As discussed earlier, increased Ca²⁺, neuronal depolarization and glutamate have been shown to inhibit the insulin-stimulated tyrosine phosphorylation of IR in hippocampal synaptic membranes and primary neurons [101, 212]. In addition to Ca²⁺ dysregulation, oxidative stress and inflammatory cytokines that are thought to be involved in the pathogenesis of AD [102,302,304-308]. These factors could also contribute to the inhibition of IR via increases in IRS and Akt serine phosphorylation. Increased IRS-1 and Akt serine phosphorylation are found in the AD brain correlated with decreased surface IR expression and tyrosine phosphorylation [309]. Ex

vivo studies show that Akt activity is triggered by A β and A β oligomers [242,310], and is responsible for mediating A β -induced microglia production of inflammatory chemokines [311]. Given the negative feedback effect of IRS-1 and Akt serine phosphorylation on IR Tyr phosphorylation, the A β /A β oligomer-induced activation of IRS and Akt could contribute to brain insulin resistance in AD. On the other hand, PI3K/Akt pathway is well known as a downstream event to be activated by IR and IGF-1R activities [170], which plays a role in insulin and IGF-1- associated neuron protection [312-314]. Interestingly, Akt activation is involved in both apoptotic and neuroprotective pathways mediated by different TNF receptors [315]. Therefore, depending on whether it is involved in a feedforward or a feedback pathway, its cellular colocalization, and its specific association with upstream signaling cascades, Akt serine phosphorylation may induce different signal transduction outcomes.

3.3.4. Ab oligomer induced insulin resistance at the blood brain barrier and other brain regions: A β oligomers might cause insulin resistance in other brain cells. For example, insulin receptor mRNA is highly concentrated at choroid plexus [101-103] where it is responsible for transport of insulin across the blood brain barrier [316]. Increased circulating A β oligomers in the brain may act on IRs that are localized at brain capillaries, particularly those at the choroid plexus. Impairment of IR at these loci would affect central insulin transport. As briefly mentioned earlier, A β oligomers can also interact with RAGE in endothelial cells of blood brain barrier to trigger production of inflammatory cytokines such as IL-6 and TNF α [111,317]. Although AD most critically affects brain regions involved in higher cognition, it is possible that at advanced stages more widespread A β oligomers distribution in the brain circulation may adversely affect neurons of other brain regions such as those in hypothalamus or neurons with glucose sensing capability. If IRs in these regions are impaired by A β oligomers, the result may be dysregulation of hypothalamic function, glucose and energy metabolism. This might explain, at least in part, why a high proportion of AD patients develop T2DM [13].

3.4 Insulin resistance as a necessary cofactor for Ab aggregation –the beginning of the vicious cycle? While the above evidence shows that neuronal insulin resistance is a result of A β oligomer toxicity, a large body of data indicates impairment of brain insulin signaling promotes amyloidogenesis. Insight may be gained from the generation of human IAPP (hIAPP) transgenic mouse model. Although hIAPP is highly aggregable compared to the rodent IAPP, the transgenic

mice overexpressing hIAPP do not produce islet amyloid aggregates despite up to 15-fold increase in plasma hIAPP [318]. Nor do the mice show any abnormality in blood glucose and insulin levels [278]. However, when the hIAPP mice islets are exposed to high concentrations of glucose in culture, extracellular IAPP amyloid aggregates are formed [319]. Similarly, a few years after their first report in 1993 [278], Hoppener and colleagues crossed the hIAPP mice with the *ob/ob* mice (mice express a mutant leptin gene and developed insulin resistance, obesity and diabetes) to produce a double transgenic model [85]. Remarkably, a significant amount of islet amyloid aggregation was observed in the islets of double transgenic hIAPP-*ob/ob* mice together with additional molecular, cellular and symptomatic alterations [85]. In *ob/ob* mice, insulin resistance resulted in an increased insulin secretion that overcomes hyperglycemia. In hIAPP-*ob/ob* mice, however, the hIAPP amyloidogenesis is accompanied by exacerbation of insulin resistance: The mice are notably more obese than *ob/ob*-only mice; and insulin secretion is reduced resulting in hyperglycemia, indicating loss of β -cell function. It is likely the loss of β -cells is caused by lower molecular weight IAPP oligomers, which show cytotoxic effects by disrupting membrane stability and inducing cell death in cultured islet β -cells [86,88-90,92,93], similar to the neuronal toxic properties of A β oligomers. On the other hand, the IAPP mature fibrils are not toxic [87,92]. From these results, it is suggested that increased hIAPP production may be essential but not sufficient for islet amyloidogenesis, whereas insulin resistance and elevated glucose is a necessary cofactor required to trigger the amyloid aggregation. However, whether and when an elevated IAPP level (locally and/or in circulation) occurs in T2DM remains to be clarified.

Similar cases can also be found in AD transgenic mice models. In the Tg2576 AD mouse model, mice fed with normal laboratory diet do not show memory deficits until at 6 months of age [54,55]. The mice maintain relatively normal circulating insulin levels and glucose metabolism until 13 months old, when plasma hyperinsulinemia becomes evident [58]. Despite high production of A β and plaque disposition, there is lack of neuronal death and neurofibrillary tangles in their brains [54,55]. However, when these mice are fed with a high fat diet, they develop non-insulin dependent diabetes mellitus (NIDDM) insulin resistance, a condition that leads to significantly advanced AD pathology and symptoms [73]. First, there is greater than 2-fold higher blood insulin levels at age of 9 month along with obesity compared to the non insulin resistant Tg2576 mice that do not show hyperinsulinaemia until age of 13 month [57]. Second, at

the same age, the levels of A β 1-40 and A β 1-42 from the hippocampus and cerebral cortex are also >2-fold higher, correlated with activation of γ -secretase and GSK3 α and GSK3 β . Third, the tyrosine phosphorylation of cerebral IR is considerably lower, as is the phosphorylation of PI3 kinase and Akt. Fourth, compared to the non insulin resistant controls, the NIDDM insulin resistant Tg2576 mice show severe impairment in water maze spatial learning [73]. Thus, similar to the case of the hIAPP-*ob/ob* mice, on the basis of high production of A β , development of insulin resistance accelerates brain amyloidogenesis, and facilitates disease progression.

An impaired IR signaling may exacerbate A β accumulation in several ways. Perhaps the most important effect of an impaired IR signaling is reflected by a weakened inhibition on glycogen synthase kinase 3 (GSK3), an important downstream node of IR signaling [320]. GSK3, including both the α and the β subunit, are thought to be critically involved in AD pathogenesis with activated GSK3 α triggering APP γ -secretase activity [321-324] thus increases A β production, and GSK3 β phosphorylating Tau [325-328] thereby promoting formation of NFT. Activation of IR signaling inhibits both GSK3 α and GSK3 β via the PI3 kinase pathway [171]. Impairment of IR function, therefore, would result in high activity of GSK3 that leads to enhanced Tau phosphorylation and A β production, exacerbation of both would certainly facilitate the disease pathologies. Indeed, specific knockout of brain IR revealed activation of GSK3 in the mouse brain [118]. Secondly, brain insulin resistance could interrupt A β clearance. A β is reported to be transported across the blood brain barrier and/or taken into microglia for clearance, a process depending on the low-density lipoprotein receptor-related protein (LRP) and its ligands ApoE and α 2-macroglobulin [329-332]. In addition A β is also cleared through local enzymatic digestion by insulin-degrading enzyme (IDE), neprilysin (NEP) and other metalloenzymes [333-335]. Insulin signaling has been reported to stimulate α 2M binding to LRP and their expression [336] and expression of IDE [337]. Furthermore, APP processing and A β transport between TGN and plasma membrane in neurons has been reported to involve IR signaling [338]. Insulin resistance, therefore, would add to accumulation of A β via interruption of both clearance and production processes [Figure2].

5. Concluding remarks

Emerging evidence in the past decade from the diabetes and AD research fields, as well as from basic neuroscience research has made great strides in understanding the molecular pathogenesis of these two degenerative diseases. It is becoming clear that T2DM and AD are linked by two common molecular pathologies, namely impaired insulin resistance and amyloidogenesis that are associated with impaired glucose metabolism and increased oxidative stress. When they co-occur in the brain, these two factors appear to form a pathological loop, in which they interact with and reinforce each other to generate cellular toxicity that leads to energy metabolism impairment and cognitive deficits. While IR impairment may result from actions of A β oligomers at multiple levels, IR desensitization accelerates A β aggregation and disease progression. Evidence supporting this loop include that IR tyrosine kinase activity and its membrane surface expression are markedly inhibited in the AD brain [67,289], and in rat primary hippocampal neurons by A β oligomers [147,212]. Conversely, T2DM is a risk factor for AD [339,340]. Insulin resistance is a trigger/accelerator for amyloidogenesis[319] as transgenic mice on a insulin resistance-inducing diet show more advanced A β deposition and memory deficits [73]. Therefore, not only do these diseases compound each other's pathologies, but interact on the same molecular pathways.

However, much is still unknown about the relationship between an essential role of insulin signaling in normal cellular function and development of T2DM and AD. One of the main issues that remains to be reconciled is that deletion of the key IR/IGF-1 signaling (IIS) genes in species including *c. elegans* [341,342], *drosophila* [343,344] and rodents [345,346] during the embryonic development results in a longer and disease-resistant life span [347], whereas diminished insulin response of IR in later age is associated with metabolic/degenerative diseases that cause high mortality. One possible explanation is that with deletion of the key insulin pathway genes throughout life, the body adopts a starvation strategy, upregulates compensatory mechanisms and lengthens lifespan to improve reproductive success. In contrast, insulin resistance in T2DM and AD is a late onset dysfunction of glucose homeostasis. To clarify this issue, novel animal models with inducible IR phosphorylation mutants (either Ser/Thr or Tyr) may mimic the late onset insulin resistance and thus provide a model to test this issue.

Another test of the hypothesis that insulin receptor signaling plays a central role in T2DM and AD, is the identification of familial mutations in the IR pathway that would increase the risk of developing AD. Point mutations in IR are associated with insulin resistance, obesity and

diabetes [348-350]. Although one isolated study has identified polymorphism of PI3K, a major downstream kinase of IR, in AD patients [351], to date, no genetic defect of IR has been identified in AD.

Additional questions include: How and why does insulin resistance promote A β aggregation? Apart from influencing A β production and Tau phosphorylation, does insulin resistance play a role in protein misfolding on the neuronal surface? Does insulin resistance interfere with A β turnover in the brain? To address these questions might require development of appropriate animal models such as inducible knockdown (or dominant negative) of IR in specific brain regions of AD transgenic mice at specific age windows, from which the specific molecular connection between brain insulin resistance and amyloidogenesis relevant to disease progress of AD may be identified. If the IR can affect synapses of the CNS, what is the source of endogenous insulin (i.e. transport from the periphery, or locally synthesized and secreted by neurons)? Is the mechanism of action direct through insulin receptor signal transduction or perhaps indirect through glucose metabolism and mitochondrial function? Lastly, while future studies are required to validate the pathological feedback loops of insulin resistance and amyloidogenesis, one can speculate that brain insulin resistance may contribute to abnormal A β turnover thereby contributing to disease progression in at least a subtype of LOAD. Thus, it may be reasonable to hypothesize that while the peripheral insulin resistance likely to proceed into T2DM (some might take more than 10 years), the neuronal insulin resistance might proceed AD. In this context, AD could be seen as a brain type of diabetes.

Reference List

1. C.T.Kodl and E.R.Sequist, Cognitive dysfunction and diabetes mellitus 1, *Endocrine Reviews* 29 (2008) 494.

2. L.C.Perlmuter, M.K.Hakami, C.Hodgson-Harrington, J.Ginsberg, J.Katz, D.E.Singer, and D.M.Nathan, Decreased cognitive function in aging non-insulin-dependent diabetic patients, *Am J Med* 77 (1984) 1043.
3. M.N.Haan, Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease, *Nat Clin Pract Neurol* 2 (2006) 159.
4. A.Ott, R.P.Stolk, F.van Harskamp, H.A.Pols, A.Hofman, and M.M.Breteler, Diabetes mellitus and the risk of dementia: The Rotterdam Study, *Neurology* 53 (1999) 1937.
5. I.Skoog, B.Lernfelt, S.Landahl, B.Palmertz, L.A.Andreasson, L.Nilsson, G.Persson, A.Oden, and A.Svanborg, 15-year longitudinal study of blood pressure and dementia, *Lancet* 347 (1996) 1141.
6. C.L.Leibson, P.C.O'Brien, E.Atkinson, P.J.Palumbo, and L.J.Melton, III, Relative contributions of incidence and survival to increasing prevalence of adult-onset diabetes mellitus: a population-based study, *Am J Epidemiol* 146 (1997) 12.
7. R.P.Stolk, H.A.Pols, S.W.Lamberts, P.T.de Jong, A.Hofman, and D.E.Grobbee, Diabetes mellitus, impaired glucose tolerance, and hyperinsulinemia in an elderly population. The Rotterdam Study, *Am J Epidemiol* 145 (1997) 24.
8. R.P.Stolk, M.M.Breteler, A.Ott, H.A.Pols, S.W.Lamberts, D.E.Grobbee, and A.Hofman, Insulin and cognitive function in an elderly population. The Rotterdam Study, *Diabetes Care* 20 (1997) 792.
9. L.Kilander, H.Nyman, M.Boberg, L.Hansson, and H.Lithell, Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men, *Hypertension* 31 (1998) 780.
10. W.B.Grant, Dietary links to Alzheimer's disease: 1999 update, *J Alzheimers. Dis* 1 (1999) 197.
11. A.Myers, P.Holmans, H.Marshall, J.Kwon, D.Meyer, D.Ramic, S.Shears, J.Booth, F.W.DeVrieze, R.Crook, M.Hamshire, R.Abraham, N.Tunstall, F.Rice, S.Carty, S.Lillystone, P.Kehoe, V.Rudrasingham, L.Jones, S.Lovestone, J.Perez-Tur, J.Williams, M.J.Owen, J.Hardy, and A.M.Goate, Susceptibility locus for Alzheimer's disease on chromosome 10, *Science* 290 (2000) 2304.
12. G.J.Petot, F.Traore, S.M.Debanne, A.J.Lerner, K.A.Smyth, and R.P.Friedland, Interactions of apolipoprotein E genotype and dietary fat intake of healthy older persons during mid-adult life, *Metabolism* 52 (2003) 279.
13. J.Janson, T.Laedtke, J.E.Parisi, P.O'Brien, R.C.Petersen, and P.C.Butler, Increased risk of type 2 diabetes in Alzheimer disease, *Diabetes* 53 (2004) 474.

14. S.Hoyer, Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis
10, *J Neural Transm.* 105 (1998) 415.
15. S.Hoyer, Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update
21, *Exp Gerontol* 35 (2000) 1363.
16. S.Hoyer, The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update
20, *J Neural Transm.* 109 (2002) 341.
17. G.S.Watson and S.Craft, Insulin resistance, inflammation, and cognition in Alzheimer's Disease: lessons for multiple sclerosis, *J Neurol Sci* 245 (2006) 21.
18. G.M.Cole and S.A.Frautschy, The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease, *Exp Gerontol* 42 (2007) 10.
19. S.M.de la Monte, M.Tong, N.Lester-Coll, M.Plater, Jr., and J.R.Wands, Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease, *J Alzheimers. Dis* 10 (2006) 89.
20. S.M.de la Monte and J.R.Wands, Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease, *J Alzheimers. Dis* 7 (2005) 45.
21. S.Hoyer, Brain glucose and energy metabolism during normal aging, *Aging (Milano.)* 2 (1990) 245.
22. P.J.Magistretti, Neuron-glia metabolic coupling and plasticity, *J Exp Biol* 209 (2006) 2304.
23. M.J.Dunne, K.E.Cosgrove, R.M.Shepherd, A.Aynsley-Green, and K.J.Lindley, Hyperinsulinism in infancy: from basic science to clinical disease, *Physiol Rev* 84 (2004) 239.
24. J.T.E.Richardson, Cognitive Function in Diabetes-Mellitus, *Neuroscience and Biobehavioral Reviews* 14 (1990) 385.
25. P.A.Tun, D.M.Nathan, and L.C.Perlmutter, Cognitive and affective disorders in elderly diabetics, *Clin Geriatr Med* 6 (1990) 731.
26. M.W.Strachan, I.J.Deary, F.M.Ewing, and B.M.Frier, Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies, *Diabetes Care* 20 (1997) 438.
27. E.L.Helkala, L.Niskanen, H.Viinamaki, J.Partanen, and M.Uusitupa, Short-term and long-term memory in elderly patients with NIDDM, *Diabetes Care* 18 (1995) 681.

28. D.de Weid, B.Bohus, and T.B.Wimersma Greidanus, Memory deficit in rats with hereditary diabetes insipidus, *Brain Res* 85 (1975) 152.
29. G.J.Biessels, A.Kamal, G.M.Ramakers, I.J.Urban, B.M.Spruijt, D.W.Erkelens, and W.H.Gispen, Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats, *Diabetes* 45 (1996) 1259.
30. E.C.McNay and R.S.Sherwin, Effect of recurrent hypoglycemia on spatial cognition and cognitive metabolism in normal and diabetic rats, *Diabetes* 53 (2004) 418.
31. E.C.McNay, A.Williamson, R.J.McCrimmon, and R.S.Sherwin, Cognitive and neural hippocampal effects of long-term moderate recurrent hypoglycemia, *Diabetes* 55 (2006) 1088.
32. J.T.Dou, M.Chen, F.Dufour, D.L.Alkon, and W.Q.Zhao, Insulin receptor signaling in long-term memory consolidation following spatial learning, *Learn. Mem.* 12 (2005) 646.
33. T.Moreira, E.Malec, C.G.Ostenson, S.Efendic, and S.Liljequist, Diabetic type II Goto-Kakizaki rats show progressively decreasing exploratory activity and learning impairments in fixed and progressive ratios of a lever-press task, *Behav Brain Res* 180 (2007) 28.
34. Z.G.Li, W.Zhang, and A.A.Sima, Alzheimer-like changes in rat models of spontaneous diabetes, *Diabetes* 56 (2007) 1817.
35. A.M.Stranahan and M.P.Mattson, Impact of Energy Intake and Expenditure on Neuronal Plasticity, *Neuromolecular. Med* (2008).
36. A.M.Stranahan, T.V.Arumugam, R.G.Cutler, K.Lee, J.M.Egan, and M.P.Mattson, Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons, *Nat Neurosci* 11 (2008) 309.
37. S.Minoshima, R.A.Koepp, K.A.Frey, M.Ishihara, and D.E.Kuhl, Stereotactic PET atlas of the human brain: aid for visual interpretation of functional brain images, *J Nucl. Med* 35 (1994) 949.
38. E.M.Reiman, R.J.Caselli, L.S.Yun, K.Chen, D.Bandy, S.Minoshima, S.N.Thibodeau, and D.Osborne, Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E, *N Engl J Med* 334 (1996) 752.
39. E.M.Reiman, R.J.Caselli, K.Chen, G.E.Alexander, D.Bandy, and J.Frost, Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease, *Proc Natl Acad Sci U S A* 98 (2001) 3334.

40. G.W.Small, A.La Rue, S.Komo, A.Kaplan, and M.A.Mandelkern, Predictors of cognitive change in middle-aged and older adults with memory loss, *Am J Psychiatry* 152 (1995) 1757.
41. G.W.Small, L.M.Ercoli, D.H.Silverman, S.C.Huang, S.Komo, S.Y.Bookheimer, H.Lavretsky, K.Miller, P.Siddarth, N.L.Rasgon, J.C.Mazziotta, S.Saxena, H.M.Wu, M.S.Mega, J.L.Cummings, A.M.Saunders, M.A.Pericak-Vance, A.D.Roses, J.R.Barrio, and M.E.Phelps, Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease, *Proc Natl Acad Sci U S A* 97 (2000) 6037.
42. M.J.de Leon, A.Convit, O.T.Wolf, C.Y.Tarshish, S.DeSanti, H.Rusinek, W.Tsui, E.Kandil, A.J.Scherer, A.Roche, A.Imossi, E.Thorn, M.Bobinski, C.Caraos, P.Lesbre, D.Schlyer, J.Poirier, B.Reisberg, and J.Fowler, Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET) 40, *Proc Natl Acad Sci U S A* 98 (2001) 10966.
43. N.L.Foster, T.N.Chase, L.Mansi, R.Brooks, P.Fedio, N.J.Patronas, and G.Di Chiro, Cortical abnormalities in Alzheimer's disease, *Ann Neurol* 16 (1984) 649.
44. R.P.Friedland, T.F.Budinger, E.Koss, and B.A.Ober, Alzheimer's disease: anterior-posterior and lateral hemispheric alterations in cortical glucose utilization, *Neurosci Lett* 53 (1985) 235.
45. E.Koss, R.P.Friedland, B.A.Ober, and W.J.Jagust, Differences in lateral hemispheric asymmetries of glucose utilization between early- and late-onset Alzheimer-type dementia, *Am J Psychiatry* 142 (1985) 638.
46. L.Mosconi, S.De Santi, J.Li, W.H.Tsui, Y.Li, M.Boppana, E.Laska, H.Rusinek, and M.J.de Leon, Hippocampal hypometabolism predicts cognitive decline from normal aging, *Neurobiol. Aging* 29 (2008) 676.
47. L.Mosconi, D.Perani, S.Sorbi, K.Herholz, B.Nacmias, V.Holthoff, E.Salmon, J.C.Baron, M.T.De Cristofaro, A.Padovani, B.Borroni, M.Franceschi, L.Bracco, and A.Pupi, MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET, *Neurology* 63 (2004) 2332.
48. L.Mosconi, W.H.Tsui, K.Herholz, A.Pupi, A.Drzejga, G.Lucignani, E.M.Reiman, V.Holthoff, E.Kalbe, S.Sorbi, J.Diehl-Schmid, R.Perneczky, F.Clerici, R.Caselli, B.Beuthien-Baumann, A.Kurz, S.Minoshima, and M.J.de Leon, Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias, *J Nucl. Med* 49 (2008) 390.
49. E.M.Reiman, K.W.Chen, G.E.Alexander, R.J.Caselli, D.Bandy, D.Osborne, A.M.Saunders, and J.Hardy, Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia

- 42, Proceedings of the National Academy of Sciences of the United States of America 101 (2004) 284.
50. J.W.Pettegrew, K.Panchalingam, W.E.Klunk, R.J.McClure, and L.R.Muenz, Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study, *Neurobiol. Aging* 15 (1994) 117.
51. A.M.Kennedy, R.S.Frackowiak, S.K.Newman, P.M.Bloomfield, J.Seaward, P.Roques, G.Lewington, V.J.Cunningham, and M.N.Rossor, Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease, *Neurosci Lett* 186 (1995) 17.
52. J.Valla, F.Gonzalez-Lima, and E.M.Reiman, FDG autoradiography reveals developmental and pathological effects of mutant amyloid in PDAPP transgenic mice, *Int J Dev Neurosci* 26 (2008) 253.
53. B.E.Needham, M.E.Wlodek, G.D.Ciccotosto, B.C.Fam, C.L.Masters, J.Proietto, S.Andrikopoulos, and R.Cappai, Identification of the Alzheimer's disease amyloid precursor protein (APP) and its homologue APLP2 as essential modulators of glucose and insulin homeostasis and growth, *J Pathol* 215 (2008) 155.
54. K.Hsiao, P.Chapman, S.Nilsen, C.Eckman, Y.Harigaya, S.Younkin, F.Yang, and G.Cole, Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice, *Science* 274 (1996) 99.
55. K.H.Ashe, Synaptic structure and function in transgenic APP mice 30, *Ann N Y Acad Sci* 924 (2000) 39.
56. M.Bigl, J.Apelt, K.Eschrich, and R.Schliebs, Cortical glucose metabolism is altered in aged transgenic Tg2576 mice that demonstrate Alzheimer plaque pathology 34, *J Neural Transm.* 110 (2003) 77.
57. W.A.Pedersen and E.R.Flynn, Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease, *Neurobiol. Dis* 17 (2004) 500.
58. C.Choeri, W.Staines, and C.Messier, Immunohistochemical localization and quantification of glucose transporters in the mouse brain 35, *Neuroscience* 111 (2002) 19.
59. C.R.Hooijmans, C.Graven, P.J.Dederen, H.Tanila, T.van Groen, and A.J.Kiliaan, Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice 54, *Brain Res* 1181 (2007) 93.
60. G.I.Bell, Lilly lecture 1990. Molecular defects in diabetes mellitus 31, *Diabetes* 40 (1991) 413.

61. S.I.Taylor, Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene, *Diabetes* 41 (1992) 1473.
62. D.Le Roith and Y.Zick, Recent advances in our understanding of insulin action and insulin resistance, *Diabetes Care* 24 (2001) 588.
63. K.A.Heidenreich, N.R.Zahniser, P.Berhanu, D.Brandenburg, and J.M.Olefsky, Structural differences between insulin receptors in the brain and peripheral target tissues 51, *J Biol Chem* 258 (1983) 8527.
64. J.Kuusisto, K.Koivisto, L.Mykkanen, E.L.Helkala, M.Vanhanen, T.Hanninen, K.Pyorala, P.Riekkinen, and M.Laakso, Essential hypertension and cognitive function. The role of hyperinsulinemia, *Hypertension* 22 (1993) 771.
65. S.Kalmijn, E.J.Feskens, L.J.Launer, T.Stijnen, and D.Kromhout, Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men 60, *Diabetologia* 38 (1995) 1096.
66. L.Frolich, D.Blum-Degen, H.G.Bernstein, S.Engelsberger, J.Humrich, S.Laufer, D.Muschner, A.Thalheimer, A.Turk, S.Hoyer, R.Zochling, K.W.Boissl, K.Jellinger, and P.Riederer, Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease 47, *J Neural Transm.* 105 (1998) 423.
67. L.Frolich, D.Blum-Degen, P.Riederer, and S.Hoyer, A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease 48, *Ann N Y Acad Sci* 893 (1999) 290.
68. E.Steen, B.M.Terry, E.J.Rivera, J.L.Cannon, T.R.Neely, R.Tavares, X.J.Xu, J.R.Wands, and S.M.de la Monte, Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?, *J Alzheimers. Dis* 7 (2005) 63.
69. S.Craft, E.Peskind, M.W.Schwartz, G.D.Schellenberg, M.Raskind, and D.Porte, Jr., Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype 37, *Neurology* 50 (1998) 164.
70. S.Craft, S.Asthana, G.Schellenberg, M.Cherrier, L.D.Baker, J.Newcomer, S.Plymate, S.Latendresse, A.Petrova, M.Raskind, E.Peskind, C.Lofgreen, and K.Grimwood, Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender 38, *Neuroendocrinology* 70 (1999) 146.
71. W.A.Pedersen, P.J.McMillan, J.J.Kulstad, J.B.Leverenz, S.Craft, and G.R.Haynatzki, Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice, *Exp Neurol* 199 (2006) 265.

72. G.S.Watson, B.A.Cholerton, M.A.Reger, L.D.Baker, S.R.Plymate, S.Asthana, M.A.Fishel, J.J.Kulstad, P.S.Green, D.G.Cook, S.E.Kahn, M.L.Keeling, and S.Craft, Preserved cognition in patients with early Alzheimer disease and amnesic mild cognitive impairment during treatment with rosiglitazone: a preliminary study, *Am. J. Geriatr. Psychiatry* 13 (2005) 950.
73. L.Ho, W.Qin, P.N.Pompl, Z.Xiang, J.Wang, Z.Zhao, Y.Peng, G.Cambareri, A.Rocher, C.V.Mobbs, P.R.Hof, and G.M.Pasinetti, Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease 53, *FASEB J* 18 (2004) 902.
74. J.Wang, L.Ho, W.Qin, A.B.Rocher, I.Seror, N.Humala, K.Maniar, G.Dolios, R.Wang, P.R.Hof, and G.M.Pasinetti, Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease, *FASEB J* 19 (2005) 659.
75. G.P.Lim, F.Calon, T.Morihara, F.Yang, B.Teter, O.Ubeda, N.Salem, Jr., S.A.Frautschy, and G.M.Cole, A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model 69, *J Neurosci* 25 (2005) 3032.
76. C.Haass, E.H.Koo, A.Mellon, A.Y.Hung, and D.J.Selkoe, Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments 50, *Nature* 357 (1992) 500.
77. M.Shoji, T.E.Golde, J.Ghiso, T.T.Cheung, S.Estus, L.M.Shaffer, X.D.Cai, D.M.McKay, R.Tintner, B.Frangione, and ., Production of the Alzheimer amyloid beta protein by normal proteolytic processing, *Science* 258 (1992) 126.
78. P.Westermark, Fine structure of islets of Langerhans in insular amyloidosis, *Virchows Arch A Pathol Pathol Anat.* 359 (1973) 1.
79. P.Westermark, C.Wernstedt, E.Wilander, D.W.Hayden, T.D.O'Brien, and K.H.Johnson, Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells, *Proc Natl Acad Sci U S A* 84 (1987) 3881.
80. G.J.Cooper, A.C.Willis, A.Clark, R.C.Turner, R.B.Sim, and K.B.Reid, Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients 36, *Proc Natl Acad Sci U S A* 84 (1987) 8628.
81. S.C.Woods, T.A.Lutz, N.Geary, and W.Langhans, Pancreatic signals controlling food intake; insulin, glucagon and amylin, *Philos. Trans R. Soc Lond B Biol Sci* 361 (2006) 1219.

82. S.Arora and Anubhuti, Role of neuropeptides in appetite regulation and obesity--a review
29, *Neuropeptides* 40 (2006) 375.
83. C.Betsholtz, L.Christmansson, U.Engstrom, F.Rorsman, V.Svensson, K.H.Johnson, and P.Westermark, Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species
32, *FEBS Lett* 251 (1989) 261.
84. P.Westermark, U.Engstrom, K.H.Johnson, G.T.Westermark, and C.Betsholtz, Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation, *Proc Natl Acad Sci U S A* 87 (1990) 5036.
85. J.W.Hoppener, C.Oosterwijk, M.G.Nieuwenhuis, G.Posthuma, J.H.Thijssen, T.M.Vroom, B.Ahren, and C.J.Lips, Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model
55, *Diabetologia* 42 (1999) 427.
86. Y.Porat, S.Kolusheva, R.Jelinek, and E.Gazit, The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies
85, *Biochemistry* 42 (2003) 10971.
87. J.D.Green, C.Goldsbury, J.Kistler, G.J.Cooper, and U.Aebi, Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation
49, *J Biol Chem* 279 (2004) 12206.
88. R.Kayed, E.Head, J.L.Thompson, T.M.McIntire, S.C.Milton, C.W.Cotman, and C.G.Glabe, Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
61, *Science* 300 (2003) 486.
89. T.A.Mirzabekov, M.C.Lin, and B.L.Kagan, Pore formation by the cytotoxic islet amyloid peptide amylin
76, *J Biol Chem* 271 (1996) 1988.
90. M.Anguiano, R.J.Nowak, and P.T.Lansbury, Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes
2, *Biochemistry* 41 (2002) 11338.
91. R.Kayed, Y.Sokolov, B.Edmonds, T.M.McIntire, S.C.Milton, J.E.Hall, and C.G.Glabe, Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases
62, *J Biol Chem* 279 (2004) 46363.

92. J.J.Meier, R.Kayed, C.Y.Lin, T.Gurlo, L.Haataja, S.Jayasinghe, R.Langen, C.G.Glabe, and P.C.Butler, Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP 74, *Am J Physiol Endocrinol Metab* 291 (2006) E1317-E1324.
93. C.J.Huang, C.Y.Lin, L.Haataja, T.Gurlo, A.E.Butler, R.A.Rizza, and P.C.Butler, High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes 59, *Diabetes* 56 (2007) 2016.
94. D.J.Selkoe, Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein 88, *Ann N Y Acad Sci* 924 (2000) 17.
95. D.J.Selkoe, Alzheimer's disease is a synaptic failure 89, *Science* 298 (2002) 789.
96. J.W.Kelly, The environmental dependency of protein folding best explains prion and amyloid diseases 63, *Proc Natl Acad Sci U S A* 95 (1998) 930.
97. C.M.Dobson, The structural basis of protein folding and its links with human disease 42, *Philos. Trans R. Soc Lond B Biol Sci* 356 (2001) 133.
98. M.Brownlee, Advanced protein glycosylation in diabetes and aging, *Annu. Rev. Med.* 46 (1995) 223.
99. J.A.Nogueira-Machado and M.M.Chaves, From hyperglycemia to AGE-RAGE interaction on the cell surface: a dangerous metabolic route for diabetic patients, *Expert. Opin. Ther. Targets.* 12 (2008) 871.
100. S.A.Small and S.Gandy, Sorting through the cell biology of Alzheimer's disease: Intracellular pathways to pathogenesis, *Neuron* 52 (2006) 15.
101. M.A.Smith, V.M.Monnier, L.M.Sayre, and G.Perry, Amyloidosis, advanced glycation end products and Alzheimer disease, *Neuroreport* 6 (1995) 1595.
102. M.A.Smith, L.M.Sayre, V.M.Monnier, and G.Perry, Radical AGEing in Alzheimer's disease, *Trends Neurosci.* 18 (1995) 172.
103. M.A.Smith, L.M.Sayre, M.P.Vitek, V.M.Monnier, and G.Perry, Early AGEing and Alzheimer's, *Nature* 374 (1995) 316.
104. H.P.Hammes, S.S.Ali, M.Uhlmann, A.Weiss, K.Federlin, K.Geisen, and M.Brownlee, Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats, *Diabetologia* 38 (1995) 269.

105. K.J.Knecht, M.S.Feather, and J.W.Baynes, Detection of 3-deoxyfructose and 3-deoxyglucosone in human urine and plasma: evidence for intermediate stages of the Maillard reaction in vivo, *Arch. Biochem. Biophys.* 294 (1992) 130.
106. T.Mitsuhashi, H.Nakayama, T.Itoh, S.Kuwajima, S.Aoki, T.Atsumi, and T.Koike, Immunochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat, *Diabetes* 42 (1993) 826.
107. H.Nakayama, T.Mitsuhashi, S.Kuwajima, S.Aoki, Y.Kuroda, T.Itoh, and S.Nakagawa, Immunochemical detection of advanced glycation end products in lens crystallins from streptozocin-induced diabetic rat, *Diabetes* 42 (1993) 345.
108. G.Munch, R.Schinzel, C.Loske, A.Wong, N.Durany, J.J.Li, H.Vlassara, M.A.Smith, G.Perry, and P.Riederer, Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts, *J. Neural Transm.* 105 (1998) 439.
109. A.M.Schmidt, O.Hori, R.Cao, S.D.Yan, J.Brett, J.L.Wautier, S.Ogawa, K.Kuwabara, M.Matsumoto, and D.Stern, RAGE: a novel cellular receptor for advanced glycation end products, *Diabetes* 45 Suppl 3 (1996) S77-S80.
110. A.Bierhaus, S.Schiekofer, M.Schwanger, M.Andrassy, P.M.Humpert, J.Chen, M.Hong, T.Luther, T.Henle, I.Kloting, M.Morcos, M.Hofmann, H.Tritschler, B.Weigle, M.Kasper, M.Smith, G.Perry, A.M.Schmidt, D.M.Stern, H.U.Haring, E.Schleicher, and P.P.Nawroth, Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB, *Diabetes* 50 (2001) 2792.
111. R.Deane, Y.S.Du, R.K.Subramanian, B.LaRue, S.Jovanovic, E.Hogg, D.Welch, L.Manness, C.Lin, J.Yu, H.Zhu, J.Ghiso, B.Frangione, A.Stern, A.M.Schmidt, D.L.Armstrong, B.Arnold, B.Liliensiek, P.Nawroth, F.Hofman, M.Kindy, D.Stern, and B.Zlokovic, RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain, *Nat. Med.* 9 (2003) 907.
112. G.Munch, J.Thome, P.Foley, R.Schinzel, and P.Riederer, Advanced glycation endproducts in ageing and Alzheimer's disease, *Brain Res. Brain Res. Rev.* 23 (1997) 134.
113. V.P.Reddy, M.E.Obrenovich, C.S.Atwood, G.Perry, and M.A.Smith, Involvement of Maillard reactions in Alzheimer disease, *Neurotox. Res.* 4 (2002) 191.
114. M.P.Vitek, K.Bhattacharya, J.M.Glendening, E.Stopa, H.Vlassara, R.Bucala, K.Manogue, and A.Cerami, Advanced glycation end products contribute to amyloidosis in Alzheimer disease, *Proc. Natl. Acad. Sci. U. S. A* 91 (1994) 4766.
115. F.Chen, D.David, A.Ferrari, and J.Gotz, Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals, *Curr. Drug Targets.* 5 (2004) 503.

116. M.Necula and J.Kuret, Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro, *J. Biol. Chem.* 279 (2004) 49694.
117. M.A.Smith, M.Rudnicka-Nawrot, P.L.Richey, D.Praprotnik, P.Mulvihill, C.A.Miller, L.M.Sayre, and G.Perry, Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease, *J. Neurochem.* 64 (1995) 2660.
118. L.W.Ko, E.C.Ko, P.Nacharaju, W.K.Liu, E.Chang, A.Kenessey, and S.H.Yen, An immunochemical study on tau glycation in paired helical filaments, *Brain Res.* 830 (1999) 301.
119. J.J.Li, M.Surini, S.Catsicas, E.Kawashima, and C.Bouras, Age-dependent accumulation of advanced glycosylation end products in human neurons, *Neurobiol. Aging* 16 (1995) 69.
120. V.V.Shuvaev, I.Laffont, J.M.Serot, J.Fujii, N.Taniguchi, and G.Siest, Increased protein glycation in cerebrospinal fluid of Alzheimer's disease, *Neurobiol. Aging* 22 (2001) 397.
121. M.A.Smith, S.L.Siedlak, P.L.Richey, R.H.Nagaraj, A.Elhammer, and G.Perry, Quantitative solubilization and analysis of insoluble paired helical filaments from Alzheimer disease, *Brain Res.* 717 (1996) 99.
122. M.O.Chaney, W.B.Stine, T.A.Kokjohn, Y.M.Kuo, C.Esh, A.Rahman, D.C.Luehrs, A.M.Schmidt, D.Stern, S.D.Yan, and A.E.Roher, RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling, *Biochim. Biophys. Acta* 1741 (2005) 199.
123. Y.S.Du, H.Zhu, J.Fu, S.F.Yan, A.Roher, W.W.Tourtellotte, T.Rajavashisth, X.Chen, G.C.Godman, D.Stern, and A.M.Schmidt, Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease, *Proc. Natl. Acad. Sci. U. S. A* 94 (1997) 5296.
124. O.Arancio, H.P.Zhang, X.Chen, C.Lin, F.Trinchese, D.Puzzo, S.Liu, A.Hegde, S.F.Yan, A.Stern, J.S.Luddy, L.F.Lue, D.G.Walker, A.Roher, M.Buttini, L.Mucke, W.Li, A.M.Schmidt, M.Kindy, P.A.Hyslop, D.M.Stern, and S.S.Du Yan, RAGE potentiates A β -induced perturbation of neuronal function in transgenic mice, *EMBO J.* 23 (2004) 4096.
125. L.F.Lue, D.G.Walker, and J.Rogers, Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures, *Neurobiol. Aging* 22 (2001) 945.
126. L.F.Lue, D.G.Walker, L.Brachova, T.G.Beach, J.Rogers, A.M.Schmidt, D.M.Stern, and S.D.Yan, Involvement of microglial receptor for advanced glycation endproducts

- (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism, *Exp. Neurol.* 171 (2001) 29.
127. P.I.Moreira, M.A.Smith, X.Zhu, A.Nunomura, R.J.Castellani, and G.Perry, Oxidative stress and neurodegeneration, *Ann. N. Y. Acad. Sci.* 1043 (2005) 545.
 128. S.D.Yan, X.Chen, J.Fu, M.Chen, H.Zhu, A.Roher, T.Slattery, L.Zhao, M.Nagashima, J.Morser, A.Migheli, P.Nawroth, D.Stern, and A.M.Schmidt, RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease, *Nature* 382 (1996) 685.
 129. S.D.Yan, D.Stern, M.D.Kane, Y.M.Kuo, H.C.Lampert, and A.E.Roher, RAGE-Abeta interactions in the pathophysiology of Alzheimer's disease, *Restor. Neurol. Neurosci.* 12 (1998) 167.
 130. N.Origlia, M.Righi, S.Capsoni, A.Cattaneo, F.Fang, D.M.Stern, J.X.Chen, A.M.Schmidt, O.Arancio, S.D.Yan, and L.Domenici, Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction, *J. Neurosci.* 28 (2008) 3521.
 131. J.Havrankova, M.Brownstein, and J.Roth, Insulin Receptors Are Widely But Unevenly Distributed in Central Nervous-System of Rat
4, *Clinical Research* 26 (1978) A491.
 132. J.Havrankova and J.Roth, Insulin Receptors Are Widely Distributed in Central Nervous-System of Rat
6, *Nature* 272 (1978) 827.
 133. J.L.Marks, D.Porte, W.L.Stahl, and D.G.Baskin, Localization of Insulin-Receptor Messenger-Rna in Rat-Brain by Insitu Hybridization
1, *Endocrinology* 127 (1990) 3234.
 134. W.Q.Zhao, H.Chen, H.Xu, E.Moore, N.Meiri, M.J.Quon, and D.L.Alkon, Brain insulin receptors and spatial memory - Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats
1, *Journal of Biological Chemistry* 274 (1999) 34893.
 135. G.A.Werther, A.Hogg, B.J.Oldfield, M.J.Mckinley, R.Figdor, A.M.Allen, and F.A.O.Mendelsohn, Localization and Characterization of Insulin-Receptors in Rat-Brain and Pituitary-Gland Using Invitro Autoradiography and Computerized Densitometry, *Endocrinology* 121 (1987) 1562.
 136. J.Shemer, M.Adamo, M.K.Raizada, D.Heffez, Y.Zick, and D.Leroith, Insulin and IGF-I stimulate phosphorylation of their respective receptors in intact neuronal and glial cells in primary culture, *J Mol Neurosci* 1 (1989) 3.

137. W.S.Young, Periventricular Hypothalamic Cells in the Rat-Brain Contain Insulin Messenger-Rna, *Neuropeptides* 8 (1986) 93.
138. D.W.Clarke, L.Mudd, F.T.Boyd, M.Fields, and M.K.Raizada, Insulin Is Released from Rat-Brain Neuronal Cells in Culture, *Journal of Neurochemistry* 47 (1986) 831.
139. L.Weil, H.Matsumoto, and D.E.Rhoads, Release of Immunoreactive Insulin from Rat-Brain Synaptosomes Under Depolarizing Conditions, *Journal of Neurochemistry* 54 (1990) 1661.
140. S.U.Devaskar, S.J.Giddings, P.A.Rajakumar, L.R.Carnaghi, R.K.Menon, and D.S.Zahm, Insulin Gene-Expression and Insulin Synthesis in Mammalian Neuronal Cells, *Journal of Biological Chemistry* 269 (1994) 8445.
141. R.Schechter, D.Beju, T.Gaffney, F.Schaefer, and L.Whetsell, Preproinsulin I and II mRNAs and insulin electron microscopic immunoreaction are present within the rat fetal nervous system, *Brain Research* 736 (1996) 16.
142. M.Wozniak, B.Rydzewski, S.P.Baker, and M.K.Raizada, The Cellular and Physiological Actions of Insulin in the Central-Nervous-System 1, *Neurochemistry International* 22 (1993) 1.
143. K.A.Heidenreich and P.R.Gilmore, Structural and Functional-Characteristics of Insulin-Receptors in Rat Neuro-Blastoma Cells, *Journal of Neurochemistry* 45 (1985) 1642.
144. M.K.Raizada, J.Shemer, J.H.Judkins, D.W.Clarke, B.A.Masters, and D.Leroith, Insulin-Receptors in the Brain - Structural and Physiological Characterization, *Neurochemical Research* 13 (1988) 297.
145. S.Seino and G.I.Bell, Alternative Splicing of Human Insulin-Receptor Messenger-Rna 7, *Biochemical and Biophysical Research Communications* 159 (1989) 312.
146. B.J.Goldstein and A.L.Dudley, The Rat Insulin-Receptor - Primary Structure and Conservation of Tissue-Specific Alternative Messenger-Rna Splicing 20, *Molecular Endocrinology* 4 (1990) 235.
147. B.J.Goldstein and A.L.Dudley, Heterogeneity of Messenger-Rna That Encodes the Rat Insulin-Receptor Is Limited to the Domain of Exon 11 - Analysis by Rna Heteroduplex Mapping, Amplification of Cdna, and Invitro Translation 3, *Diabetes* 41 (1992) 1293.
148. K.A.Kenner, J.Kusari, and K.A.Heidenreich, Cdna Sequence-Analysis of the Human Brain Insulin-Receptor 1, *Biochemical and Biophysical Research Communications* 217 (1995) 304.
149. Z.Huang, N.L.Bodkin, H.K.Ortmeyer, B.C.Hansen, and A.R.Shuldiner, Hyperinsulinemia Is Associated with Altered Insulin-Receptor Messenger-Rna

- Splicing in Muscle of the Spontaneously Obese-Diabetic Rhesus-Monkey
7, *Journal of Clinical Investigation* 94 (1994) 1289.
150. P.Sbraccia, M.DAdamo, F.Leonetti, S.Caiola, P.Iozzo, A.Giaccari, A.Buongiorno, and G.Tamburrano, Chronic primary hyperinsulinaemia is associated with altered insulin receptor mRNA splicing in muscle of patients with insulinoma
6, *Diabetologia* 39 (1996) 220.
 151. M.Schubert, D.Gautam, D.Surjo, K.Ueki, S.Baudler, D.Schubert, T.Kondo, J.Alber, N.Galldiks, E.Kustermann, S.Arndt, A.H.Jacobs, W.Krone, C.R.Kahn, and J.C.Bruning, Role for neuronal insulin resistance in neurodegenerative diseases
4, *Proceedings of the National Academy of Sciences of the United States of America* 101 (2004) 3100.
 152. W.Q.Zhao, H.Chen, M.J.Quon, and D.L.Alkon, Insulin and the insulin receptor in experimental models of learning and memory
41, *European Journal of Pharmacology* 490 (2004) 71.
 153. L.P.van der Heide, G.M.J.Ramakers, and M.P.Smidt, Insulin signaling in the central nervous system: Learning to survive
1, *Progress in Neurobiology* 79 (2006) 205.
 154. S.C.Woods and D.Porte, Jr., The central nervous system, pancreatic hormones, feeding, and obesity, *Adv. Metab Disord* 9 (1978) 283.
 155. S.C.Woods, D.M.Dorsa, D.P.Figlewicz, D.G.Baskin, L.J.Stein, A.J.Sipols, and D.Porte, Importance of the Brain Insulin System to Food-Intake
8, *Appetite* 6 (1985) 216.
 156. D.G.Baskin, D.P.Figlewicz, S.C.Woods, D.Porte, and D.M.Dorsa, Insulin in the Brain
2, *Annual Review of Physiology* 49 (1987) 335.
 157. J.C.Bruning, D.Gautam, J.A.Gillette, W.Krone, and R.C.Kahn, Brain-specific disruption of the insulin receptor gene in mice results in obesity, hyperinsulinemia and dyslipidemia
3, *Diabetes* 49 (2000) A279.
 158. S.C.Woods, M.W.Schwartz, D.G.Baskin, and R.J.Seeley, Food intake and the regulation of body weight
11, *Annual Review of Psychology* 51 (2000) 255.
 159. M.W.Schwartz, S.C.Woods, D.Porte, Jr., R.J.Seeley, and D.G.Baskin, Central nervous system control of food intake, *Nature* 404 (2000) 661.
 160. L.Plum, M.Schubert, and J.C.Bruning, The role of insulin receptor signaling in the brain
5, *Trends in Endocrinology and Metabolism* 16 (2005) 59.

161. H.L.Fehm, W.Kern, and A.Peters, The selfish brain: competition for energy resources
3, *Hypothalamic Integration of Energy Metabolism* 153 (2006) 129.
162. K.Gerozissis, Brain insulin and feeding: a bi-directional communication
3, *European Journal of Pharmacology* 490 (2004) 59.
163. K.Gerozissis, Brain insulin, energy and glucose homeostasis; genes, environment and
metabolic pathologies
1, *European Journal of Pharmacology* 585 (2008) 38.
164. M.Rotte, C.Baerecke, G.Pottag, S.Klose, E.Kanneberg, H.J.Heinze, and H.Lehner, Insulin affects the neuronal response in the medial temporal lobe in humans
1, *Neuroendocrinology* 81 (2005) 49.
165. H.Eichenbaum, Hippocampus: Cognitive processes and neural representations that
underlie declarative memory
1, *Neuron* 44 (2004) 109.
166. W.Kern, J.Born, H.Schreiber, and H.L.Fehm, Central nervous system effects of
intranasally administered insulin during euglycemia in men
19, *Diabetes* 48 (1999) 557.
167. W.Kern, B.Fruehwald-Schultes, A.Peters, C.Dodt, J.Born, and H.L.Fehm, Effects of
insulin on neurophysiological and behavioural measures of cognitive function in
healthy humans
15, *Diabetes* 48 (1999) A438.
168. W.Kern, A.Peters, B.Fruehwald-Schultes, E.Deininger, J.Born, and H.L.Fehm,
Improving influence of insulin on cognitive functions in humans
2, *Neuroendocrinology* 74 (2001) 270.
169. C.R.Park, R.J.Seeley, S.Craft, and S.C.Woods, Intracerebroventricular insulin enhances
memory in a passive-avoidance task
52, *Physiology & Behavior* 68 (2000) 509.
170. C.Benedict, M.Hallschmid, B.Schultes, J.Born, and W.Kern, Intranasal insulin to
improve memory function in humans
2, *Neuroendocrinology* 86 (2007) 136.
171. U.Stockhorst, D.de Fries, H.J.Steingrueber, and W.A.Scherbaum, Insulin and the CNS:
effects on food intake, memory, and endocrine parameters and the role of
intranasal insulin administration in humans
1, *Physiology & Behavior* 83 (2004) 47.
172. M.A.Reger, G.S.Watson, P.S.Green, C.W.Wilkinson, L.D.Baker, B.Cholerton,
M.A.Fishel, S.R.Plymate, J.C.S.Breitner, W.DeGroot, P.Mehta, and S.Craft,
Intranasal insulin improves cognition and modulates beta-amyloid in early AD
2, *Neurology* 70 (2008) 440.

173. M.A.Reger, G.S.Watson, P.S.Green, L.D.Baker, B.Cholerton, M.A.Fishel, S.R.Plymate, M.M.Cherrier, G.D.Schellenberg, W.H.Frey, and S.Craft, Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults
1, *Journal of Alzheimers Disease* 13 (2008) 323.
174. M.Tomioka, T.Adachi, H.Suzuki, H.Kunitomo, W.R.Schafer, and Y.Iino, The insulin/PI 3-kinase pathway regulates salt chemotaxis learning in *Caenorhabditis elegans*
4, *Neuron* 51 (2006) 613.
175. T.V.P.Bliss and G.L.Collingridge, A Synaptic Model of Memory - Long-Term Potentiation in the Hippocampus
1, *Nature* 361 (1993) 31.
176. A.Artola and W.Singer, Long-term depression of excitatory synaptic transmission and its relationship to long-term potentiation, *Trends Neurosci* 16 (1993) 480.
177. M.Zhuo and R.D.Hawkins, Long-term depression: a learning-related type of synaptic plasticity in the mammalian central nervous system, *Rev Neurosci* 6 (1995) 259.
178. G.J.Biessels, A.Kamal, I.J.A.Urban, B.M.Spruijt, D.W.Erkelens, and W.H.Gispén, Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment
1, *Brain Research* 800 (1998) 125.
179. M.Di Luca, L.Ruts, F.Gardoni, F.Cattabeni, G.J.Biessels, and W.H.Gispén, NMDA receptor subunits are modified transcriptionally and post-translationally in the brain of streptozotocin-diabetic rats
2, *Diabetologia* 42 (1999) 693.
180. M.Townsend, T.Mehta, and D.J.Selkoe, Soluble A beta inhibits specific signal transduction cascades common to the insulin receptor pathway
1, *Journal of Biological Chemistry* 282 (2007) 33305.
181. J.Lisman and S.Raghavachari, A unified model of the presynaptic and postsynaptic changes during LTP at CA1 synapses, *Sci STKE*. 2006 (2006) re11.
182. J.E.Lisman, S.Raghavachari, and R.W.Tsien, The sequence of events that underlie quantal transmission at central glutamatergic synapses, *Nat Rev Neurosci* 8 (2007) 597.
183. R.Malinow and R.C.Malenka, AMPA receptor trafficking and synaptic plasticity, *Annu Rev Neurosci* 25 (2002) 103.
184. D.S.Bredt and R.A.Nicoll, AMPA receptor trafficking at excitatory synapses, *Neuron* 40 (2003) 361.

185. H.Y.Man, W.Ju, G.Ahmadian, and Y.T.Wang, Intracellular trafficking of AMPA receptors in synaptic plasticity
1, Cellular and Molecular Life Sciences 57 (2000) 1526.
186. Y.T.Wang and D.J.Linden, Expression of cerebellar long-term depression requires postsynaptic clathrin-mediated endocytosis
1, Neuron 25 (2000) 635.
187. Y.T.Wang, Probing the role of AMPAR endocytosis and long-term depression in behavioural sensitization: relevance to treatment of brain disorders, including drug addiction
3, British Journal of Pharmacology 153 (2008) S389-S395.
188. H.Y.Man, J.W.Lin, W.H.Ju, G.Ahmadian, L.D.Liu, L.E.Becker, M.Sheng, and Y.T.Wang, Regulation of AMPA receptor-mediated synaptic transmission by clathrin-dependent receptor internalization
2, Neuron 25 (2000) 649.
189. J.W.Lin, W.Ju, K.Foster, S.H.Lee, G.Ahmadian, M.Wyszynski, Y.T.Wang, and M.Sheng, Distinct molecular mechanisms and divergent endocytotic pathways of AMPA receptor internalization, Nat Neurosci 3 (2000) 1282.
190. E.C.Beattie, R.C.Carroll, X.Yu, W.Morishita, H.Yasuda, M.von Zastrow, and R.C.Malenka, Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD, Nat Neurosci 3 (2000) 1291.
191. Q.Zhou, M.Xiao, and R.A.Nicoll, Contribution of cytoskeleton to the internalization of AMPA receptors, Proc Natl Acad Sci U S A 98 (2001) 1261.
192. G.L.Dalton, Y.T.Wang, S.B.Floresco, and A.G.Phillips, Disruption of AMPA Receptor Endocytosis Impairs the Extinction, but not Acquisition of Learned Fear, Neuropsychopharmacology (2007).
193. L.P.van der Heide, A.Kamal, A.Artola, W.H.Gispén, and G.M.J.Ramakers, Insulin modulates hippocampal activity-dependent synaptic plasticity in a N-methyl-D-aspartate receptor and phosphatidyl-inositol-3-kinase-dependent manner
1, Journal of Neurochemistry 94 (2005) 1158.
194. S.L.Chiu, C.M.Chen, and H.T.Cline, Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo, Neuron 58 (2008) 708.
195. Q.Wan, Z.G.Xiong, Y.H.Man, C.A.Ackerley, J.Braunton, W.Y.Lu, L.E.Becker, J.F.MacDonald, and Y.T.Wang, Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin
1, Nature 388 (1997) 686.

196. X.H.Ma, P.Zhong, Z.L.Gu, J.Feng, and Z.Yan, Muscarinic potentiation of GABA(A) receptor currents is gated by insulin signaling in the prefrontal cortex
1, *Journal of Neuroscience* 23 (2003) 1159.
197. S.M.Vetiska, G.Ahmadian, W.Ju, L.Liu, M.P.Wymann, and Y.T.Wang, GABA(A) receptor-associated phosphoinositide 3-kinase is required for insulin-induced recruitment of postsynaptic GABA(A) receptors, *Neuropharmacology* 52 (2007) 146.
198. V.B.Caraiscos, R.P.Bonin, J.G.Newell, E.Czerwinska, J.F.MacDonald, and B.A.Orser, Insulin increases the potency of glycine at ionotropic glycine receptors
1, *Molecular Pharmacology* 71 (2007) 1277.
199. J.W.Lynch, Molecular structure and function of the glycine receptor chloride channel
1, *Physiological Reviews* 84 (2004) 1051.
200. B.L.Seely, D.R.Reichart, Y.Takata, C.Yip, and J.M.Olefsky, A Functional Assessment of Insulin Insulin-Like Growth-Factor-I Hybrid Receptors
2, *Endocrinology* 136 (1995) 1635.
201. Z.G.Li, W.Zhang, G.Grunberger, and A.A.Sima, Hippocampal neuronal apoptosis in type 1 diabetes, *Brain Res* 946 (2002) 221.
202. M.Kasuga, Y.Zick, D.L.Blith, F.A.Karlsson, H.U.Haring, and C.R.Kahn, Insulin Stimulation of Phosphorylation of the Beta-Subunit of the Insulin-Receptor - Formation of Both Phosphoserine and Phosphotyrosine
3, *Journal of Biological Chemistry* 257 (1982) 9891.
203. C.R.Kahn and F.Folli, Molecular Determinants of Insulin Action
3, *Hormone Research* 39 (1993) 93.
204. C.M.Taniguchi, B.Emanuelli, and C.R.Kahn, Critical nodes in signalling pathways: insights into insulin action
4, *Nature Reviews Molecular Cell Biology* 7 (2006) 85.
205. A.H.Khan and J.E.Pessin, Insulin regulation of glucose uptake: A complex interplay of intracellular signalling pathways
4, *Diabetologia* 45 (2002) 1475.
206. D.A.E.Cross, D.R.Alessi, P.Cohen, M.Andjelkovich, and B.A.Hemmings, Inhibition of Glycogen-Synthase Kinase-3 by Insulin-Mediated by Protein-Kinase-B
1, *Nature* 378 (1995) 785.
207. J.Girard, D.Perdereau, F.Foufelle, C.Pripbuus, and P.Ferre, Regulation of Lipogenic Enzyme Gene-Expression by Nutrients and Hormones
12, *Faseb Journal* 8 (1994) 36.

208. J.C.H.Byon, A.B.Kusari, and J.Kusari, Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction
1, *Molecular and Cellular Biochemistry* 182 (1998) 101.
209. B.P.Kennedy and C.Ramachandran, Protein tyrosine phosphatase-1B in diabetes
6, *Biochemical Pharmacology* 60 (2000) 877.
210. M.P.Czech, The Nature and Regulation of the Insulin-Receptor - Structure and Function
6, *Annual Review of Physiology* 47 (1985) 357.
211. J.L.Zachayus, G.Cherqui, and C.Plas, Protein-Kinase-C and Insulin-Receptor Beta-Subunit Serine Phosphorylation in Cultured Fetal-Rat Hepatocytes
1, *Molecular and Cellular Endocrinology* 105 (1994) 11.
212. I.Mothe and E.VanObberghen, Phosphorylation of insulin receptor substrate-1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action
2, *Journal of Biological Chemistry* 271 (1996) 11222.
213. H.EldarFinkelman and E.G.Krebs, Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action
1, *Proceedings of the National Academy of Sciences of the United States of America* 94 (1997) 9660.
214. V.Strack, A.M.Hennige, J.Krutzfeldt, B.Bossenmaier, H.H.Klein, M.Kellerer, R.Lammers, and H.U.Haring, Serine residues 994 and 1023/25 are important for insulin receptor kinase inhibition by protein kinase C isoforms beta 2 and theta
5, *Diabetologia* 43 (2000) 443.
215. G.I.Shulman, Cellular mechanisms of insulin resistance
5, *Journal of Clinical Investigation* 106 (2000) 171.
216. A.R.Saltiel and J.E.Pessin, Insulin signaling pathways in time and space
12, *Trends in Cell Biology* 12 (2002) 65.
217. C.Morisco, G.Condorelli, V.Trimarco, A.Bellis, C.Marrone, G.Condorelli, J.Sadoshima, and B.Trimarco, Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes
2, *Circulation Research* 96 (2005) 180.
218. B.Draznin, Molecular mechanisms of insulin resistance: Serine phosphorylation of insulin receptor substrate-1 and increased expression of p85 alpha - The two sides of a coin
1, *Diabetes* 55 (2006) 2392.
219. J.F.Youngren, Regulation of insulin receptor function
2, *Cellular and Molecular Life Sciences* 64 (2007) 873.

220. S.Takayama, M.F.White, V.Lauris, and C.R.Kahn, Phorbol esters modulate insulin receptor phosphorylation and insulin action in cultured hepatoma cells, *Proc Natl Acad Sci U S A* 81 (1984) 7797.
221. R.A.Roth, F.Liu, and J.E.Chin, Biochemical-Mechanisms of Insulin-Resistance 9, *Hormone Research* 41 (1994) 51.
222. T.S.Pillay, S.Xiao, and J.M.Olefsky, Glucose-induced phosphorylation of the insulin receptor functional effects and characterization of phosphorylation sites 2, *Journal of Clinical Investigation* 97 (1996) 613.
223. R.Tian, Another role for the celebrity Akt and insulin resistance 3, *Circulation Research* 96 (2005) 139.
224. K.De Fea and R.A.Roth, Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function by mitogen-activated protein kinase, *J Biol Chem* 272 (1997) 31400.
225. K.De Fea and R.A.Roth, Protein kinase C modulation of insulin receptor substrate-1 tyrosine phosphorylation requires serine 612, *Biochemistry* 36 (1997) 12939.
226. M.L.Standaert and R.J.Pollet, Receptor-Mediated Translocation and Degradation of Insulin in Muscle-Tissue 6, *Clinical Research* 31 (1983) A853.
227. J.L.Carpentier, M.Fehlmann, E.VanObberghen, P.Gorden, and L.Orci, Redistribution of I-125-Insulin on the Surface of Rat Hepatocytes As A Function of Dissociation Time 2, *Diabetes* 34 (1985) 1002.
228. G.M.Di Guglielmo, P.G.Drake, P.C.Baass, F.Authier, B.I.Posner, and J.J.M.Bergeron, Insulin receptor internalization and signalling 2, *Molecular and Cellular Biochemistry* 182 (1998) 59.
229. S.Marshall, A.Green, and J.M.Olefsky, Evidence for recycling of insulin receptors in isolated rat adipocytes, *J Biol Chem* 256 (1981) 11464.
230. V.P.Knutson, Proteolytic Processing of the Insulin-Receptor Beta-Subunit Is Associated with Insulin-Induced Receptor Down-Regulation 1, *Journal of Biological Chemistry* 266 (1991) 15656.
231. E.R.Kandel and J.H.Schwartz, Molecular-Biology of Learning - Modulation of Transmitter Release 1, *Science* 218 (1982) 433.
232. B.Bank, A.DeWeer, A.M.Kuzirian, H.Rasmussen, and D.L.Alkon, Classical conditioning induces long-term translocation of protein kinase C in rabbit hippocampal CA1 cells, *Proc Natl Acad Sci U S A* 85 (1988) 1988.

233. T.R.Soderling, K.Fukunaga, D.P.Rich, Y.L.Fong, K.Smith, and R.J.Colbran, Regulation of Brain Ca-2+/Calmodulin-Dependent Protein Kinase-Ii
17, *Advances in Second Messenger and Phosphoprotein Research* 24 (1990) 206.
234. T.R.Soderling, Calcium/Calmodulin-Dependent Protein-Kinase .2. Role in Learning and Memory
15, *Molecular and Cellular Biochemistry* 128 (1993) 93.
235. T.R.Soderling, S.E.Tan, E.Mcglademcculloh, H.Yamamoto, and K.Fukunaga, Excitatory Interactions Between Glutamate Receptors and Protein-Kinases
14, *Journal of Neurobiology* 25 (1994) 304.
236. X.Nogues, Protein kinase C, learning and memory: A circular determinism between physiology and behaviour
1, *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 21 (1997) 507.
237. E.A.VanderZee and B.R.K.Douma, Historical review of research on protein kinase C in learning and memory
2, *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 21 (1997) 379.
238. Y.Elgersma and A.J.Silva, Molecular mechanisms of synaptic plasticity and memory
1, *Current Opinion in Neurobiology* 9 (1999) 209.
239. J.P.Adams and J.D.Sweatt, Molecular psychology: Roles for the ERK MAP kinase cascade in memory
8, *Annual Review of Pharmacology and Toxicology* 42 (2002) 135.
240. J.Jaworski, S.Spangler, D.P.Seeburg, C.C.Hoogenraad, and M.Sheng, Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway
1, *Journal of Neuroscience* 25 (2005) 11300.
241. S.Peineau, C.Taghibiglou, C.Bradley, T.P.Wong, L.D.Liu, J.Lu, E.Lo, D.C.Wu, E.Saule, T.Bouschet, P.Matthews, J.T.R.Isaac, Z.A.Bortolotto, Y.T.Wang, and G.L.Collingridge, UP inhibits LTD in the hippocampus via regulation of GSK3 beta
1, *Neuron* 53 (2007) 703.
242. W.Q.Zhao, F.G.De Felice, S.Fernandez, H.Chen, M.P.Lambert, M.J.Quon, G.A.Krafft, and W.L.Klein, Amyloid beta oligomers induce impairment of neuronal insulin receptors, *Faseb Journal* 22 (2008) 246.
243. M.P.Mattson, Calcium and neurodegeneration
2, *Aging Cell* 6 (2007) 337.

244. M.P.Mattson, Mitochondrial regulation of neuronal plasticity
4, *Neurochemical Research* 32 (2007) 707.
245. J.T.Greenamyre and A.B.Young, Excitatory Amino-Acids and Alzheimers-Disease
1, *Neurobiology of Aging* 10 (1989) 593.
246. J.J.Palop, J.Chin, E.D.Roberson, J.Wang, M.T.Thwin, N.Bien-Ly, J.Yoo, K.O.Ho,
G.Q.Yu, A.Kreitzer, S.Finkbeiner, J.L.Noebels, and L.Mucke, Aberrant
excitatory neuronal activity and compensatory remodeling of inhibitory
hippocampal circuits in mouse models of Alzheimer's disease
5, *Neuron* 55 (2007) 697.
247. G.Sweeney and A.Klip, Regulation of the Na⁺/K⁺-ATPase by insulin: Why and how?
6, *Molecular and Cellular Biochemistry* 182 (1998) 121.
248. D.J.Selkoe and D.Schenk, Alzheimer's disease: Molecular understanding predicts
amyloid-based therapeutics
11, *Annual Review of Pharmacology and Toxicology* 43 (2003) 545.
249. R.E.Tanzi and L.Bertram, Twenty years of the Alzheimer's disease amyloid hypothesis:
A genetic perspective
9, *Cell* 120 (2005) 545.
250. S.Gandy, The role of cerebral amyloid beta accumulation in common forms of
Alzheimer disease, *J Clin Invest* 115 (2005) 1121.
251. A.Goate, M.C.Chartierharlin, M.Mullan, J.Brown, F.Crawford, L.Fidani, L.Giuffra,
A.Haynes, N.Irving, L.James, R.Mant, P.Newton, K.Rooke, P.Roques, C.Talbot,
M.Pericakvance, A.Roses, R.Williamson, M.Rossor, M.Owen, and J.Hardy,
Segregation of A Missense Mutation in the Amyloid Precursor Protein Gene with
Familial Alzheimers-Disease
4, *Nature* 349 (1991) 704.
252. E.Levy, M.D.Carman, I.J.Fernandezmadrid, M.D.Power, I.Lieberburg, S.G.Vanduinen,
G.T.A.M.Bots, W.Luyendijk, and B.Frangione, Mutation of the Alzheimers-
Disease Amyloid Gene in Hereditary Cerebral-Hemorrhage, Dutch Type
3, *Science* 248 (1990) 1124.
253. D.R.Borchelt, G.Thinakaran, C.B.Eckman, M.K.Lee, F.Davenport, T.Ratovitsky,
C.M.Prada, G.Kim, S.Seekins, D.Yager, H.H.Slunt, R.Wang, M.Seeger,
A.I.Levey, S.E.Gandy, N.G.Copeland, N.A.Jenkins, D.L.Price, and S.G.Younkin,
Familial Alzheimer's disease-linked presenilin 1 variants elevate A beta 1-42/1-40
ratio in vitro and in vivo
1, *Neuron* 17 (1996) 1005.
254. K.Duff, C.Eckman, C.Zehr, X. Yu, C.M.Prada, J.Pereztur, M.Hutton, L.Buee,
Y.Harigaya, D.Yager, D.Morgan, M.N.Gordon, L.Holcomb, L.Refolo, B.Zenk,
J.Hardy, and S.Younkin, Increased amyloid-beta 42(43) in brains of mice

- expressing mutant presenilin 1
1, *Nature* 383 (1996) 710.
255. D.Scheuner, C.Eckman, M.Jensen, X.Song, M.Citron, N.Suzuki, T.D.Bird, J.Hardy, M.Hutton, W.Kukull, E.Larson, E.LevyLahad, M.Viitanen, E.Peskind, P.Poorkaj, G.Schellenberg, R.Tanzi, W.Wasco, L.Lannfelt, D.Selkoe, and S.Youngkin, Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
1, *Nature Medicine* 2 (1996) 864.
256. M.Citron, D.Westaway, W.M.Xia, G.Carlson, T.Diehl, G.Levesque, K.JohnsonWood, M.Lee, P.Seubert, A.Davis, D.Kholodenko, R.Motter, R.Sherrington, B.Perry, H.Yao, R.Strome, I.Lieberburg, J.Rommens, S.Kim, D.Schenk, P.Fraser, P.S.Hyslop, and D.J.Selkoe, Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice
2, *Nature Medicine* 3 (1997) 67.
257. A.Kinoshita, T.Shah, M.M.Tangredi, D.K.Strickland, and B.T.Hyman, The intracellular domain of the low density lipoprotein receptor-related protein modulates transactivation mediated by amyloid precursor protein and Fe65
1, *Journal of Biological Chemistry* 278 (2003) 41182.
258. S.A.Small and S.Gandy, Sorting through the cell biology of Alzheimer's disease: Intracellular pathways to pathogenesis
1, *Neuron* 52 (2006) 15.
259. G.K.Gouras, C.G.Almeida, and R.H.Takahashi, Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease, *Neurobiol. Aging* 26 (2005) 1235.
260. W.L.Klein, G.A.Krafft, and C.E.Finch, Targeting small A beta oligomers: the solution to an Alzheimer's disease conundrum?, *Trends in Neurosciences* 24 (2001) 219.
261. D.J.Selkoe, Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein, *Ann N Y Acad Sci* 924 (2000) 17.
262. D.J.Selkoe, Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior, *Behav Brain Res* 192 (2008) 106.
263. C.Hilbich, B.Kisterswoike, J.Reed, C.L.Masters, and K.Beyreuther, Human and Rodent Sequence Analogs of Alzheimers Amyloid Beta-A4 Share Similar Properties and Can be Solubilized in Buffers of Ph 7.4
2, *European Journal of Biochemistry* 201 (1991) 61.
264. D.Burdick, B.Soreghan, M.Kwon, J.Kosmoski, M.Knauer, A.Henschen, J.Yates, C.Cotman, and C.Glabe, Assembly and Aggregation Properties of Synthetic

Alzheimers A4/Beta Amyloid Peptide Analogs

1, Journal of Biological Chemistry 267 (1992) 546.

265. J.T.Jarrett, E.P.Berger, and P.T.Lansbury, The Carboxy Terminus of the Beta-Amyloid Protein Is Critical for the Seeding of Amyloid Formation - Implications for the Pathogenesis of Alzheimers-Disease
1, Biochemistry 32 (1993) 4693.
266. W.L.Klein, G.A.Krafft, and C.E.Finch, Targeting small A beta oligomers: the solution to an Alzheimer's disease conundrum?
4, Trends in Neurosciences 24 (2001) 219.
267. D.M.Walsh, I.Klyubin, J.V.Fadeeva, M.J.Rowan, and D.J.Selkoe, Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition
4, Biochemical Society Transactions 30 (2002) 552.
268. J.Naslund, V.Haroutunian, R.Mohs, K.L.Davis, P.Davies, P.Greengard, and J.D.Buxbaum, Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline, JAMA 283 (2000) 1571.
269. M.P.Lambert, A.K.Barlow, B.A.Chromy, C.Edwards, R.Freed, M.Liosatos, T.E.Morgan, I.Rozovsky, B.Trommer, K.L.Viola, P.Wals, C.Zhang, C.E.Finch, G.A.Krafft, and W.L.Klein, Diffusible, nonfibrillar ligands derived from A beta(1-42) are potent central nervous system neurotoxins, Proceedings of the National Academy of Sciences of the United States of America 95 (1998) 6448.
270. S.M.Catalano, E.C.Dodson, D.A.Henze, J.G.Joyce, G.A.Krafft, and G.G.Kinney, The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease, Curr. Top. Med. Chem. 6 (2006) 597.
271. Y.S.Gong, L.Chang, K.L.Viola, P.N.Lacor, M.P.Lambert, C.E.Finch, G.A.Krafft, and W.L.Klein, Alzheimer's disease-affected brain: Presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss
4, Proceedings of the National Academy of Sciences of the United States of America 100 (2003) 10417.
272. D.G.Georganopoulou, L.Chang, J.M.Nam, C.S.Thaxton, E.J.Mufson, W.L.Klein, and C.A.Mirkin, Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease
1, Proceedings of the National Academy of Sciences of the United States of America 102 (2005) 2273.
273. P.N.Lacor, M.C.Buniel, P.W.Furlow, A.S.Clemente, P.T.Velasco, M.Wood, K.L.Viola, and W.L.Klein, A beta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease
1, Journal of Neuroscience 27 (2007) 796.

274. S.Lesne, M.T.Koh, L.Kotilinek, R.Kayed, C.G.Glabe, A.Yang, M.Gallagher, and K.H.Ashe, A specific amyloid-beta protein assembly in the brain impairs memory, *Nature* 440 (2006) 352.
275. I.H.Cheng, K.Scarce-Levie, J.Legleiter, J.J.Palop, H.Gerstein, N.Bien-Ly, J.Puolivali, S.Lesne, K.H.Ashe, P.J.Muchowski, and L.Mucke, Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models, *J Biol Chem* 282 (2007) 23818.
276. D.M.Walsh, I.Klyubin, G.M.Shankar, M.Townsend, J.V.Fadeeva, V.Betts, M.B.Podlisny, J.P.Cleary, K.H.Ashe, M.J.Rowan, and D.J.Selkoe, The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention, *Biochem Soc Trans* 33 (2005) 1087.
277. D.M.Walsh, B.P.Tseng, R.E.Rydel, M.B.Podlisny, and D.J.Selkoe, The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain 3, *Biochemistry* 39 (2000) 10831.
278. M.Townsend, J.P.Cleary, T.Mehta, J.Hofmeister, S.Lesne, E.O'Hare, D.M.Walsh, and D.J.Selkoe, Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers 3, *Annals of Neurology* 60 (2006) 668.
279. M.Townsend, G.M.Shankar, T.Mehta, D.M.Walsh, and D.J.Selkoe, Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers 4, *Journal of Physiology-London* 572 (2006) 477.
280. I.Klyubin, V.Betts, A.T.Welzel, K.Blennow, H.Zetterberg, A.Wallin, C.A.Lemere, W.K.Cullen, Y.Peng, T.Wisniewski, D.J.Selkoe, R.Anwyl, D.M.Walsh, and M.J.Rowan, Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: Prevention by systemic passive immunization 1, *Journal of Neuroscience* 28 (2008) 4231.
281. G.M.Shankar, S.Li, T.H.Mehta, A.Garcia-Munoz, N.E.Shepardson, I.Smith, F.M.Brett, M.A.Farrell, M.J.Rowan, C.A.Lemere, C.M.Regan, D.M.Walsh, B.L.Sabatini, and D.J.Selkoe, Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory, *Nat Med* (2008).
282. P.N.Lacor, M.C.Buniel, L.Chang, S.J.Fernandez, Y.S.Gong, K.L.Viola, M.P.Lambert, P.T.Velasco, E.H.Bigio, C.E.Finch, G.A.Krafft, and W.L.Klein, Synaptic targeting by Alzheimer's-related amyloid beta oligomers, *Journal of Neuroscience* 24 (2004) 10191.
283. G.M.Shankar, B.L.Bloodgood, M.Townsend, D.M.Walsh, D.J.Selkoe, and B.L.Sabatini, Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent

signaling pathway

1, *Journal of Neuroscience* 27 (2007) 2866.

284. M.P.Lambert, P.T.Velasco, L.Chang, K.L.Viola, S.Fernandez, P.N.Lacor, D.Khuon, Y.S.Gong, E.H.Bigio, P.Shaw, F.G.De Felice, G.A.Krafft, and W.L.Klein, Monoclonal antibodies that target pathological assemblies of A beta, *Journal of Neurochemistry* 100 (2007) 23.
285. P.J.Shughrue, P.J.Acton, R.S.Breese, W.Q.Zhao, E.Chen-Dodson, R.W.Hepler, A.L.Wolfe, M.Matthews, G.J.Heidecker, J.G.Joyce, S.A.Villarreal, and G.G.Kinney, Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons, *Neurobiol. Aging* (2008).
286. B.A.Yankner, T.Lu, and P.Loerch, The aging brain, *Annu Rev Pathol* 3 (2008) 41.
287. E.M.Snyder, Y.Nong, C.G.Almeida, S.Paul, T.Moran, E.Y.Choi, A.C.Nairn, M.W.Salter, P.J.Lombroso, G.K.Gouras, and P.Greengard, Regulation of NMDA receptor trafficking by amyloid-beta, *Nature Neuroscience* 8 (2005) 1051.
288. C.C.Lee, Y.M.Kuo, C.C.Huang, and K.S.Hsu, Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation, *Neurobiol. Aging* (2007).
289. A.M.Moloney, R.J.Griffin, S.Timmons, R.O'Connor, R.Ravid, and C.O'Neill, Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling, *Neurobiol. Aging* (2008).
290. L.Xie, E.Helmerhorst, K.Taddei, B.Plewright, W.van Bronswijk, and R.Martins, Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor, *Journal of Neuroscience* 22 (2002).
291. W.Q.Qiu and M.F.Folstein, Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis 1, *Neurobiology of Aging* 27 (2006) 190.
292. H.Hsieh, J.Boehm, C.Sato, T.Iwatsubo, T.Tomita, S.Sisodia, and R.Malinow, AMPAR removal underlies A beta-induced synaptic depression and dendritic spine loss, *Neuron* 52 (2006) 831.
293. G.Hotamisligil, Stressed out about obesity and insulin resistance - Author's comments 15, *Nature Medicine* 12 (2006) 42.
294. G.S.Hotamisligil, The role of TNF alpha and TNF receptors in obesity and insulin resistance 18, *Journal of Internal Medicine* 245 (1999) 621.
295. J.Hirosami, G.Tuncman, L.F.Chang, C.Z.Gorgun, K.T.Uysal, K.Maeda, M.Karin, and G.S.Hotamisligil, A central role for JNK in obesity and insulin resistance 1, *Nature* 420 (2002) 333.

296. V.Aguirre, T.Uchida, L.Yenush, R.Davis, and M.F.White, The c-Jun NH₂-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307), *Journal of Biological Chemistry* 275 (2000) 9047.
297. M.F.White, IRS proteins and the common path to diabetes 15, *American Journal of Physiology-Endocrinology and Metabolism* 283 (2002) E413-E422.
298. L.S.Harrington, G.M.Findlay, A.Gray, T.Tolkacheva, S.Wigfield, H.Rebholz, J.Barnett, N.R.Leslie, S.Cheng, P.R.Shepherd, I.Gout, C.P.Downes, and R.E.Lamb, The TSC1-2 tumor suppressor controls insulin-P13K signaling via regulation of IRS proteins, *Journal of Cell Biology* 166 (2004) 213.
299. S.I.Itani, Q.Zhou, W.J.Pories, K.G.MacDonald, and G.L.Dohm, Involvement of protein kinase C in human skeletal muscle insulin resistance and obesity, *Diabetes* 49 (2000) 1353.
300. S.I.Itani, W.J.Pories, K.G.MacDonald, and G.L.Dohm, Increased protein kinase C theta in skeletal muscle of diabetic patients, *Metabolism-Clinical and Experimental* 50 (2001) 553.
301. O.J.Shah, Z.Y.Wang, and T.Hunter, Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies, *Current Biology* 14 (2004) 1650.
302. M.P.Mattson, S.W.Barger, K.Furukawa, A.J.Bruce, T.Wyss-Coray, R.J.Mark, and L.Mucke, Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease, *Brain Res Brain Res Rev* 23 (1997) 47.
303. L.Ragolia and N.Begum, Protein phosphatase-1 and insulin action, *Molecular and Cellular Biochemistry* 182 (1998) 49.
304. J.J.Palop, B.Jones, L.Kekoni, J.Chin, G.Q.Yu, J.Raber, E.Maslah, and L.Mucke, Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits, *Proc Natl Acad Sci U S A* 100 (2003) 9572.
305. A.G.Pearson, U.T.Byrne, G.A.MacGibbon, R.L.Faull, and M.Dragunow, Activated c-Jun is present in neurofibrillary tangles in Alzheimer's disease brains, *Neurosci Lett* 398 (2006) 246.
306. A.Thakur, X.Wang, S.L.Siedlak, G.Perry, M.A.Smith, and X.Zhu, c-Jun phosphorylation in Alzheimer disease, *J Neurosci Res* 85 (2007) 1668.
307. M.A.Smith, K.Hirai, K.Hsiao, M.A.Pappolla, P.L.Harris, S.L.Siedlak, M.Tabaton, and G.Perry, Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress, *J. Neurochem.* 70 (1998) 2212.

308. M.A.Smith, C.A.Rottkamp, A.Nunomura, A.K.Raina, and G.Perry, Oxidative stress in Alzheimer's disease, *Biochim. Biophys. Acta* 1502 (2000) 139.
309. R.J.Griffin, A.Moloney, M.Kelliher, J.A.Johnston, R.Ravid, P.Dockery, R.O'Connor, and C.O'Neill, Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology, *Journal of Neurochemistry* 93 (2005) 105.
310. J.J.Abbott, D.R.Howlett, P.T.Francis, and R.J.Williams, A beta(1-42) modulation of Akt phosphorylation via alpha 7 nAChR and NMDA receptors, *Neurobiology of Aging* 29 (2008) 992.
311. S.Ito, M.Sawada, M.Haneda, Y.Ishida, and K.Isobe, Amyloid-beta peptides induce several chemokine mRNA expressions in the primary microglia and Ra2 cell line via the PI3K/Akt and/or ERK pathway, *Neurosci. Res.* 56 (2006) 294.
312. A.I.Duarte, P.Santos, C.R.Oliveira, M.S.Santos, and A.C.Rego, Insulin neuroprotection against oxidative stress is mediated by Akt and GSK-3beta signaling pathways and changes in protein expression, *Biochim. Biophys. Acta* 1783 (2008) 994.
313. P.Kenchappa, A.Yadav, G.Singh, S.Nandana, and K.Banerjee, Rescue of TNFalpha-inhibited neuronal cells by IGF-1 involves Akt and c-Jun N-terminal kinases, *J. Neurosci. Res.* 76 (2004) 466.
314. X.R.Yu, G.R.Jia, G.D.Gao, S.H.Wang, Y.Han, and W.Cao, Neuroprotection of insulin against oxidative stress-induced apoptosis in cultured retinal neurons: involvement of phosphoinositide 3-kinase/Akt signal pathway, *Acta Biochim. Biophys. Sin. (Shanghai)* 38 (2006) 241.
315. L.Marchetti, M.Klein, K.Schlett, K.Pfizenmaier, and U.L.Eisel, Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway, *J. Biol. Chem.* 279 (2004) 32869.
316. W.A.Banks, The source of cerebral insulin
5, *European Journal of Pharmacology* 490 (2004) 5.
317. X.Zhu, M.A.Smith, K.Honda, G.Aliev, P.I.Moreira, A.Nunomura, G.Casadesus, P.L.Harris, S.L.Siedlak, and G.Perry, Vascular oxidative stress in Alzheimer disease, *J. Neurol. Sci.* 257 (2007) 240.
318. J.W.M.Hoppener, J.S.Verbeek, E.J.P.Dekoning, C.Oosterwijk, K.L.Vanhulst, H.J.Visserversnooy, F.M.A.Hofhuis, S.Vangaalen, M.J.H.Berends, W.H.L.Hackeng, H.S.Jansz, J.F.Morris, A.Clark, P.J.A.Capel, and C.J.M.Lips, Chronic Overproduction of Islet Amyloid Polypeptide Amylin in Transgenic Mice - Iyosomal Localization of Human Islet Amyloid Polypeptide and Lack of

Marked Hyperglycemia Or Hyperinsulinemia
1, *Diabetologia* 36 (1993) 1258.

319. E.J.de Koning, E.R.Morris, F.M.Hofhuis, G.Posthuma, J.W.Hoppener, J.F.Morris, P.J.Capel, A.Clark, and J.S.Verbeek, Intra- and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide, *Proc Natl Acad Sci U S A* 91 (1994) 8467.
320. S.Frame and D.Zheleva, Targeting glycogen synthase kinase-3 in insulin signalling 2, *Expert Opinion on Therapeutic Targets* 10 (2006) 429.
321. C.J.Phiel, C.A.Wilson, V.M.Lee, and P.S.Klein, GSK-3 α regulates production of Alzheimer's disease amyloid-beta peptides, *Nature* 423 (2003) 435.
322. J.Ryder, S.Yuan, and B.H.Ni, Akt/GSK3 beta serine/threonine kinases: evidence for a signalling pathway mediated by familial Alzheimer's disease mutations 1, *Cellular Signalling* 16 (2004) 187.
323. A.Takashima, GSK-3 is essential in the pathogenesis of Alzheimer's disease, *J Alzheimers. Dis* 9 (2006) 309.
324. G.Tesco and R.E.Tanzi, GSK3 beta forms a tetrameric complex with endogenous PS1-CTF/NTF and beta-catenin - Effects of the D257/D385A and FAD-linked mutations 1, *Molecular Basis of Dementia* 920 (2000) 227.
325. C.A.Grimes and R.S.Jope, The multifaceted roles of glycogen synthase kinase 3 beta in cellular signaling 2, *Progress in Neurobiology* 65 (2001) 391.
326. M.D.Kaytor and H.T.Orr, The GSK3 beta signaling cascade and neurodegenerative disease, *Curr Opin Neurobiol.* 12 (2002) 275.
327. M.P.Mazanetz and P.M.Fischer, Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases, *Nat Rev Drug Discov* 6 (2007) 464.
328. D.Muyllaert, A.Kremer, T.Jaworski, P.Borghgraef, H.Devijver, S.Croes, I.Dewachter, and F.Van Leuven, Glycogen synthase kinase-3 β , or a link between amyloid and tau pathology?, *Genes Brain Behav* 7 Suppl 1 (2008) 57.
329. M.E.Harris-White and S.A.Frautschy, Low density lipoprotein receptor-related proteins (LRPs), Alzheimer's and cognition, *Curr Drug Targets CNS Neurol Disord* 4 (2005) 469.
330. S.R.Hughes, O.Khorkova, S.Goyal, J.Knaeblein, J.Heroux, N.G.Riedel, and S.Sahasrabudhe, Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation, *Proc Natl Acad Sci U S A* 95 (1998) 3275.

331. R.D.Moir and R.E.Tanzi, LRP-mediated clearance of Abeta is inhibited by KPI-containing isoforms of APP, *Curr Alzheimer Res* 2 (2005) 269.
332. W.Q.Qiu, W.Borth, Z.Ye, C.Haass, D.B.Teplow, and D.J.Selkoe, Degradation of amyloid beta-protein by a serine protease-alpha(2)-macroglobulin complex 1, *Journal of Biological Chemistry* 271 (1996) 8443.
333. I.S.Fulcher, R.Matsas, A.J.Turner, and A.J.Kenny, Kidney neutral endopeptidase and the hydrolysis of enkephalin by synaptic membranes show similar sensitivity to inhibitors, *Biochem J* 203 (1982) 519.
334. W.Q.Qiu, D.M.Walsh, Z.Ye, K.Vekrellis, J.Zhang, M.B.Podlisny, M.R.Rosner, A.Safavi, L.B.Hersh, and D.J.Selkoe, Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation, *J Biol Chem* 273 (1998) 32730.
335. A.J.Turner, R.E.Isaac, and D.Coates, The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function, *Bioessays* 23 (2001) 261.
336. U.K.Misra, G.Gawdi, M.Gonzalez-Gronow, and S.V.Pizzo, Coordinate regulation of the alpha(2)-macroglobulin signaling receptor and the low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor by insulin 1, *Journal of Biological Chemistry* 274 (1999) 25785.
337. L.X.Zhao, B.Teter, T.Morihara, G.P.Lim, S.S.Ambegaokar, O.J.Ubeda, S.A.Frautschy, and G.M.Cole, Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: Implications for Alzheimer's disease intervention 1, *Journal of Neuroscience* 24 (2004) 11120.
338. L.Gasparini, G.K.Gouras, R.Wang, R.S.Gross, M.F.Beal, P.Greengard, and H.X.Xu, Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling 5, *Journal of Neuroscience* 21 (2001) 2561.
339. G.J.Biessels and L.J.Kappelle, Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology?, *Biochemical Society Transactions* 33 (2005) 1041.
340. C.Messier, Diabetes, Alzheimer's disease and apolipoprotein genotype, *Experimental Gerontology* 38 (2003) 941.
341. D.Gems and L.Partridge, Insulin/IGF signalling and ageing: seeing the bigger picture 1, *Current Opinion in Genetics & Development* 11 (2001) 287.
342. C.A.Wolkow, K.D.Kimura, M.S.Lee, and G.Ruvkun, Regulation of C-elegans life-span by insulinlike signaling in the nervous system 1, *Science* 290 (2000) 147.

343. D.J.Clancy, D.Gems, L.G.Harshman, S.Oldham, H.Stocker, E.Hafen, S.J.Leevers, and L.Partridge, Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein
1, *Science* 292 (2001) 104.
344. M.Tatar, A.Kopelman, D.Epstein, M.P.Tu, C.M.Yin, and R.S.Garofalo, A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function
3, *Science* 292 (2001) 107.
345. M.Bluher, B.B.Kahn, and C.R.Kahn, Extended longevity in mice lacking the insulin receptor in adipose tissue
10, *Science* 299 (2003) 572.
346. C.Selman, S.Lingard, A.I.Choudhury, R.L.Batterham, M.Claret, M.Clements, F.Ramadani, K.Okkenhaug, E.Schuster, E.Blanc, M.D.Piper, H.Al Qassab, J.R.Speakman, D.Carmignac, I.C.A.Robinson, J.M.Thornton, D.Gems, L.Partridge, and D.J.Withers, Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice
2, *Faseb Journal* 22 (2008) 807.
347. M.D.W.Piper, C.Selman, J.J.McElwee, and L.Partridge, Separating cause from effect: how does insulin/IGF signalling control lifespan in worms, flies and mice?
2, *Journal of Internal Medicine* 263 (2008) 179.
348. Y.Ebina, E.Araki, M.Taira, F.Shimada, M.Mori, C.S.Craik, K.Siddle, S.B.Pierce, R.A.Roth, and W.J.Rutter, Replacement of lysine residue 1030 in the putative ATP-binding region of the insulin receptor abolishes insulin- and antibody-stimulated glucose uptake and receptor kinase activity, *Proc Natl Acad Sci U S A* 84 (1987) 704.
349. S.I.Taylor, T.Kadowaki, H.Kadowaki, D.Accili, A.Cama, and C.McKeon, Mutations in insulin-receptor gene in insulin-resistant patients, *Diabetes Care* 13 (1990) 257.
350. A.Cama, S.M.de la Luz, L.Ottini, T.Kadowaki, P.Gorden, J.Imperato-McGinley, and S.I.Taylor, A mutation in the tyrosine kinase domain of the insulin receptor associated with insulin resistance in an obese woman, *J Clin Endocrinol Metab* 73 (1991) 894.
351. D.Liolitsa, J.Powell, and S.Lovestone, Genetic variability in the insulin signalling pathway may contribute to the risk of late onset Alzheimer's disease
1, *Journal of Neurology Neurosurgery and Psychiatry* 73 (2002) 261.
352. W.Q. Zhao, J.T. Dou, Q.Y. Liu and D.L. Alkon, Evidence for locally produced insulin in the adult rat brain as a neuroactive peptide 32nd SNF Meeting (2002). Poster M-28, #375.12


Figure legends

Figure 1 ***Hypothetical schematic showing synaptic interactions of insulin receptor with neurotransmitter receptors.*** Upon binding of the neurotransmitter glutamate, the AMPA-type glutamate receptor triggers a depolarization of the synaptic membrane. In response to the shift in membrane potential, NMDA-type glutamate receptors are relieved of the voltage-dependent Mg^{2+} block and coupled with glutamate binding, results in activation of the NMDA receptor and Ca^{2+} influx. The high concentration of Ca^{2+} (HCa^{2+}) influx acts as a second messenger to trigger activation of a variety of Ca^{2+} -dependent protein kinases that are required for formation and maintenance of long-term potentiation. On the other hand, insulin activation of insulin receptors (IRs) activates endocytotic pathways to internalize synaptic AMPA receptors. Removal of AMPA receptor from the synapses is associated with long-term depression (LTD) similar to that induced by low concentrations of Ca^{2+} (LCa^{2+}). Activation of insulin signaling also potentiates GABA transmission by recruiting GABA(A) receptors to the membrane surface. The balance of glutamatergic and GABAergic transmission are required to maintain proper brain function, while LTP and LTD-like processes are involved in regulating the relative strength of synaptic inputs required for the storage of memory. Therefore, IR signaling may play a role in modulating the excitability of the synaptic membrane as well as synaptic plasticity. At the same time, IR function is affected by synaptic activity. Ca^{2+} -dependent kinases that are activated by synaptic activity can exert an inhibitory effect on IR tyrosine kinase function by increasing serine and threonine phosphorylation of IRs and/or IR substrates. Under conditions of abnormal Ca^{2+} regulation, often found in AD, insulin receptor function may be adversely affected, thereby contributing to decreased insulin sensitivity.

Figure 2 ***A hypothetical pathological loop of insulin resistance and Ab accumulation:*** Increased $A\beta$ and $A\beta$ oligomers in the brain may cause neuronal insulin resistance at multiple levels. First $A\beta$ may disrupt insulin receptor function by downregulating membrane surface IR via internalization, desensitizing the receptor or by direct substrate competition. Second, $A\beta$ may inhibit of IR tyrosine kinase signaling by increasing intracellular Ca^{2+} , thereby activating select serine/threonine kinases, which in


turn phosphorylate IRs and IRS. Third, A β may induce microglia to produce inflammatory cytokines such as TNF α as well as its effectors free fatty acids (FFA) and JNK. The consequences of impaired IR signaling include accelerating disease progression, perhaps by activation of GSK3 leading to hyperphosphorylation of tau. Impaired IR function could also promote A β aggregation by increasing A β production and impeding transport and clearance of A β . Thus brain insulin resistance and A β aggregation/accumulation reinforce each other to drive the disease to more advanced stages.

Zhao & Townsend, Fig. 1



ACCE

Zhao & Townsend, Fig. 2



ACCEPTED